|
humans |
72 |
|
male |
58 |
|
female |
55 |
|
adult |
54 |
|
middle aged |
51 |
|
adolescent |
30 |
|
aged |
30 |
|
bone marrow transplantation |
26 |
|
retrospective studies |
23 |
|
prospective studies |
21 |
|
treatment outcome |
21 |
|
child |
20 |
|
base sequence |
17 |
|
bone marrow transplantation - adverse effects |
17 |
|
transplantation, homologous |
17 |
|
polymerase chain reaction |
16 |
|
aged, 80 and over |
15 |
|
child, preschool |
15 |
|
follow-up studies |
15 |
|
mutation |
15 |
|
prevalence |
15 |
|
chinese |
14 |
|
hematopoietic stem cell transplantation |
13 |
|
molecular sequence data |
13 |
|
polymerase chain reaction - methods |
13 |
|
prognosis |
13 |
|
rhizopus microsporus |
13 |
|
species index: fungi |
13 |
|
animals |
12 |
|
antibiotic prophylaxis |
12 |
|
china |
12 |
|
immunoglobulin heavy chains - genetics |
12 |
|
interventions |
12 |
|
recurrence |
12 |
|
risk factors |
12 |
|
acute disease |
11 |
|
antiviral agents - therapeutic use |
11 |
|
asian continental ancestry group |
11 |
|
dna primers |
11 |
|
hematopoietic stem cell transplantation - adverse effects |
11 |
|
hematopoietic stem cell transplantation - adverse effects - methods |
11 |
|
immunophenotyping |
11 |
|
incidence |
11 |
|
leukemia |
11 |
|
medical sciences |
11 |
|
tissue donors |
11 |
|
translocation, genetic |
11 |
|
tumor cells, cultured |
11 |
|
cohort studies |
10 |
|
dna methylation |
10 |
|
hong kong - epidemiology |
10 |
|
infant |
10 |
|
reverse transcriptase polymerase chain reaction |
10 |
|
tomography, x-ray computed |
10 |
|
antigens, cd44 - genetics - metabolism |
9 |
|
antineoplastic agents - pharmacology |
9 |
|
fatal outcome |
9 |
|
graft survival |
9 |
|
graft vs host disease |
9 |
|
histocompatibility testing |
9 |
|
influenza vaccines - administration and dosage |
9 |
|
killer cells, natural - metabolism |
9 |
|
leukemia, lymphocytic, chronic, b-cell - genetics |
9 |
|
longitudinal studies |
9 |
|
lymphoma - genetics |
9 |
|
lymphoma, follicular - genetics - pathology |
9 |
|
lymphoma, large b-cell, diffuse - genetics - pathology |
9 |
|
myocardial infarction - mortality - prevention and control |
9 |
|
neoplasm recurrence, local |
9 |
|
nuclear proteins - biosynthesis - genetics |
9 |
|
pcr |
9 |
|
pneumococcal vaccines - administration and dosage |
9 |
|
proto-oncogene proteins - genetics |
9 |
|
proto-oncogene proteins c-bcl-6 |
9 |
|
remission induction |
9 |
|
stomach neoplasms - genetics - pathology |
9 |
|
stroke - mortality - prevention and control |
9 |
|
survival analysis |
9 |
|
survival rate |
9 |
|
transcription factors - genetics |
9 |
|
vaccination - methods |
9 |
|
adaptor proteins, signal transducing |
8 |
|
alleles |
8 |
|
antineoplastic combined chemotherapy protocols - administration & dosage - adverse effects - therapeutic use |
8 |
|
antineoplastic combined chemotherapy protocols - therapeutic use |
8 |
|
china - epidemiology |
8 |
|
dexamethasone - administration & dosage - adverse effects |
8 |
|
disease progression |
8 |
|
disease-free survival |
8 |
|
dna mutational analysis |
8 |
|
dna, viral - analysis |
8 |
|
dna-binding proteins - genetics |
8 |
|
gene expression regulation, neoplastic |
8 |
|
gene rearrangement |
8 |
|
hematopoiesis |
8 |
|
hepatitis b surface antigens - immunology |
8 |
|
heterozygote |
8 |
|
in situ hybridization |
8 |
|
magnetic resonance imaging |
8 |
|
myeloma |
8 |
|
neoplasm proteins - genetics |
8 |
|
older patients |
8 |
|
pneumococcal vaccination |
8 |
|
promoter regions, genetic |
8 |
|
randomized controlled trial |
8 |
|
sensitivity and specificity |
8 |
|
transplantation |
8 |
|
vincristine - administration & dosage |
8 |
|
viral load |
8 |
|
virus activation |
8 |
|
adoptive transfer |
7 |
|
antineoplastic agents - adverse effects |
7 |
|
apoptosis - drug effects |
7 |
|
biopsy |
7 |
|
bmt |
7 |
|
bone marrow |
7 |
|
bone marrow transplant |
7 |
|
cd56 |
7 |
|
clone cells |
7 |
|
combined modality therapy |
7 |
|
gene expression |
7 |
|
genotype |
7 |
|
hematologic neoplasms - complications - therapy |
7 |
|
hepatitis b surface antigens - blood |
7 |
|
histocompatibility - immunology |
7 |
|
hla-dr antigens |
7 |
|
hong kong |
7 |
|
hypermethylation |
7 |
|
immunosuppression - adverse effects |
7 |
|
immunosuppressive agents - therapeutic use |
7 |
|
killer cells, natural - pathology |
7 |
|
lamivudine - therapeutic use |
7 |
|
leukocytes - virology |
7 |
|
liver - pathology |
7 |
|
lymphoma |
7 |
|
lymphoma - epidemiology - genetics |
7 |
|
microrna |
7 |
|
neoplasm, residual |
7 |
|
nuclear family |
7 |
|
post-transplantation lymphoproliferative disease |
7 |
|
reverse transcriptase polymerase chain reaction - methods |
7 |
|
sequence homology, nucleic acid |
7 |
|
sex factors |
7 |
|
solid organ transplantation |
7 |
|
stomach neoplasms - epidemiology - genetics |
7 |
|
stomach neoplasms - genetics |
7 |
|
urine - virology |
7 |
|
virus replication - drug effects |
7 |
|
acute promyelocytic leukaemia |
6 |
|
adaptor proteins, signal transducing - genetics - metabolism |
6 |
|
allogeneic stem cell transplantation |
6 |
|
antibodies, monoclonal - administration & dosage |
6 |
|
antibodies, monoclonal, murine-derived |
6 |
|
antigens, cd - blood |
6 |
|
antineoplastic agents - administration & dosage |
6 |
|
apoptosis |
6 |
|
bk virus - isolation & purification - physiology |
6 |
|
blotting, southern |
6 |
|
bone marrow - pathology |
6 |
|
bone marrow aspiration |
6 |
|
bone marrow transplantation - methods |
6 |
|
candida tropicalis fungaemia |
6 |
|
carrier proteins - biosynthesis - genetics |
6 |
|
cell line, tumor |
6 |
|
cell nucleus - genetics - pathology |
6 |
|
cfu-f |
6 |
|
cyclophosphamide - administration & dosage |
6 |
|
cytarabine - administration & dosage |
6 |
|
diarrhea - microbiology |
6 |
|
dna, complementary - genetics |
6 |
|
essential thrombocythemia |
6 |
|
etoposide - administration & dosage |
6 |
|
fluorodeoxyglucose f18 - diagnostic use |
6 |
|
gastrointestinal diseases - microbiology |
6 |
|
gene frequency |
6 |
|
gene rearrangement, t-lymphocyte |
6 |
|
graft vs host disease - drug therapy - etiology - pathology |
6 |
|
graft vs host disease - epidemiology |
6 |
|
gram-positive bacteria - isolation & purification |
6 |
|
gram-positive bacterial infections - microbiology |
6 |
|
haematological malignancies |
6 |
|
haemorrhagic cystitis |
6 |
|
hematologic neoplasms - genetics |
6 |
|
hepatitis b virus |
6 |
|
hsct |
6 |
|
immunocompromised host |
6 |
|
immunoenzyme techniques |
6 |
|
immunohistochemistry |
6 |
|
jak2 |
6 |
|
karyotyping |
6 |
|
killer cells, natural |
6 |
|
killer cells, natural - immunology - pathology |
6 |
|
leukemia - therapy |
6 |
|
leukemia, myelogenous, chronic, bcr-abl positive - therapy |
6 |
|
liver function tests |
6 |
|
lymphoma, non-hodgkin - genetics |
6 |
|
lymphoma, t-cell - genetics - immunology - pathology |
6 |
|
lymphoma, t-cell - genetics - metabolism |
6 |
|
lymphoma, t-cell - genetics - pathology |
6 |
|
mesenchymal stromal cell |
6 |
|
mitoxantrone - administration & dosage - adverse effects |
6 |
|
neoplasm metastasis |
6 |
|
nf-kappa b - metabolism |
6 |
|
nk-cell lymphoma |
6 |
|
non‐hodgkin's lymphoma |
6 |
|
nose |
6 |
|
nose neoplasms - genetics - metabolism |
6 |
|
platelet count |
6 |
|
polymorphism, genetic |
6 |
|
precursor cell lymphoblastic leukemia-lymphoma - genetics |
6 |
|
predictive value of tests |
6 |
|
prednisone - administration & dosage |
6 |
|
prognostic factors |
6 |
|
promoter regions, genetic - genetics |
6 |
|
receptors, antigen, t-cell, gamma-delta - genetics |
6 |
|
reference values |
6 |
|
rna, messenger - genetics |
6 |
|
severity of illness index |
6 |
|
signal transduction - genetics |
6 |
|
staged approach |
6 |
|
stem cell transplantation - adverse effects |
6 |
|
steroids |
6 |
|
transplantation, homologous - adverse effects |
6 |
|
vidarabine - administration & dosage - adverse effects - analogs & derivatives |
6 |
|
vtd |
6 |
|
young adult |
6 |
|
acute lymphoblastic leukemia |
5 |
|
acyclovir - therapeutic use |
5 |
|
age factors |
5 |
|
aldehyde dehydrogenase - analysis |
5 |
|
animals, genetically modified |
5 |
|
animals, newborn |
5 |
|
anti-bacterial agents - pharmacology - therapeutic use |
5 |
|
antigens, cd - analysis |
5 |
|
antigens, cd56 - analysis |
5 |
|
antigens, neoplasm - analysis |
5 |
|
antineoplastic agents - therapeutic use |
5 |
|
antineoplastic combined chemotherapy protocols - adverse effects - therapeutic use |
5 |
|
antiviral |
5 |
|
aspergillosis - etiology |
5 |
|
aspergillus - isolation & purification |
5 |
|
azacitidine - analogs & derivatives - pharmacology |
5 |
|
azithromycin |
5 |
|
bacteremia - complications - epidemiology - etiology |
5 |
|
bacteria - isolation & purification |
5 |
|
beta-thalassemia - blood - immunology - therapy |
5 |
|
bleomycin - administration & dosage |
5 |
|
blood platelets - microbiology |
5 |
|
bone marrow transplantation - adverse effects - immunology |
5 |
|
bone marrow transplantation - immunology |
5 |
|
boronic acids - therapeutic use |
5 |
|
bronchiolitis obliterans syndrome (bos) |
5 |
|
carrier state |
5 |
|
case-control studies |
5 |
|
catheterization - adverse effects |
5 |
|
chronic disease |
5 |
|
ciprofloxacin - pharmacology - therapeutic use |
5 |
|
clonality |
5 |
|
cmv |
5 |
|
cofactors |
5 |
|
cord blood stem cell |
5 |
|
cytomegalovirus - drug effects - genetics - isolation & purification |
5 |
|
diagnosis, differential |
5 |
|
dli |
5 |
|
dna, viral - blood |
5 |
|
dna, viral - blood - drug effects |
5 |
|
dna-binding proteins - biosynthesis - genetics |
5 |
|
doxorubicin - administration & dosage |
5 |
|
drug screening assays, antitumor |
5 |
|
emergencies |
5 |
|
encephalities |
5 |
|
epigenesis, genetic |
5 |
|
epigenesis, genetic - genetics |
5 |
|
exons |
5 |
|
ferritins - blood |
5 |
|
fetal blood |
5 |
|
fetal hemoglobin |
5 |
|
fetal hemoglobin - biosynthesis |
5 |
|
fetal tissue transplantation |
5 |
|
fever - etiology - therapy |
5 |
|
flow cytometry |
5 |
|
fnd |
5 |
|
fusarium |
5 |
|
gene expression profiling |
5 |
|
gene rearrangement, delta-chain t-cell antigen receptor |
5 |
|
gene silencing |
5 |
|
hematopoietic sct (hsct) |
5 |
|
hematopoietic stem cell transplantation - methods |
5 |
|
hepatitis b - complications - etiology |
5 |
|
hepatitis b antibodies - blood |
5 |
|
herpesviridae infections - blood - drug therapy - etiology |
5 |
|
herpesvirus 4, human - isolation & purification |
5 |
|
herpesvirus 6, human - drug effects - genetics - isolation & purification |
5 |
|
herpesvirus 7, human - drug effects - genetics - isolation & purification |
5 |
|
hla antigens - genetics |
5 |
|
hla typing |
5 |
|
homing |
5 |
|
idiopathic thrombocytopenic purpura |
5 |
|
immunoglobulins - chemistry |
5 |
|
in situ hybridization, fluorescence |
5 |
|
indolent lymphoma |
5 |
|
inhibitory concentration 50 |
5 |
|
iron overload |
5 |
|
leucovorin - administration & dosage |
5 |
|
leukaemia |
5 |
|
leukemia, myeloid - diagnosis - pathology |
5 |
|
leukemia, myeloid, acute - genetics |
5 |
|
leukemia, prolymphocytic, t-cell - drug therapy - ethnology |
5 |
|
leukocyte count |
5 |
|
leukocytes, mononuclear - virology |
5 |
|
liver diseases - drug therapy - etiology |
5 |
|
liver failure - etiology - surgery |
5 |
|
liver gvhd |
5 |
|
liver transplantation |
5 |
|
living donors |
5 |
|
living related donor |
5 |
|
lymphocyte transfusion - adverse effects |
5 |
|
lymphoma - therapy |
5 |
|
lymphoma, b-cell - drug therapy - ethnology |
5 |
|
lymphoma, non-hodgkin - drug therapy |
5 |
|
lymphoma, non-hodgkin - drug therapy - ethnology |
5 |
|
lymphoma, t-cell - epidemiology - pathology - therapy |
5 |
|
marrow transplantation |
5 |
|
mature t-cell lymphoma |
5 |
|
membrane proteins - genetics |
5 |
|
methotrexate - administration & dosage |
5 |
|
micrornas - genetics |
5 |
|
models, biological |
5 |
|
multiple myeloma - drug therapy - pathology |
5 |
|
multiple myeloma - genetics - pathology |
5 |
|
mycobacterium infections - etiology - microbiology |
5 |
|
myeloablative agonists - therapeutic use |
5 |
|
myelosuppression |
5 |
|
neoplasm transplantation |
5 |
|
neoplastic stem cells - pathology |
5 |
|
nk cell lymphoma |
5 |
|
non-hodgkin's lymphoma |
5 |
|
nontuberculous mycobacterium |
5 |
|
orthotopic liver transplantation |
5 |
|
phosphorylation |
5 |
|
platelet transfusion - adverse effects |
5 |
|
polycythemia vera |
5 |
|
polyoma bk virus |
5 |
|
polyomavirus infections - prevention & control - virology |
5 |
|
precursor cell lymphoblastic leukemia-lymphoma - pathology |
5 |
|
proportional hazards models |
5 |
|
protein transport |
5 |
|
recurrence - prevention & control |
5 |
|
relapse |
5 |
|
reproducibility of results |
5 |
|
respiratory tract infections - etiology - microbiology |
5 |
|
reverse transcriptase inhibitors - therapeutic use |
5 |
|
rna, viral |
5 |
|
signal transduction |
5 |
|
stem cell transplantation |
5 |
|
thrombocytosis - genetics |
5 |
|
time factors |
5 |
|
transplantation conditioning |
5 |
|
transplantation, autologous |
5 |
|
tumor markers, biological - metabolism |
5 |
|
tumor virus infections - prevention & control - virology |
5 |
|
zebrafish |
5 |
|
β-thalassemia major |
5 |
|
acute myeloid leukaemia |
4 |
|
acute myeloid leukemia |
4 |
|
acute myeloid leukemic |
4 |
|
acute promyelocytic leukemia |
4 |
|
adenoviridae - genetics - isolation & purification |
4 |
|
adenoviridae - isolation & purification |
4 |
|
adenoviridae infections - etiology - pathology |
4 |
|
administration, oral |
4 |
|
adult acute lymphoblastic leukemia |
4 |
|
akt |
4 |
|
alanine transaminase - blood |
4 |
|
alkaline phosphatase - blood |
4 |
|
all-trans retinoic acid |
4 |
|
allogeneic bone marrow transplantation |
4 |
|
alpha-thalassemia - blood - complications - therapy |
4 |
|
alpha-thalassemia - complications - physiopathology |
4 |
|
amino acid substitution |
4 |
|
aml |
4 |
|
anti-bacterial agents - administration & dosage - pharmacology - toxicity |
4 |
|
antibodies, antinuclear - analysis |
4 |
|
antibodies, monoclonal, humanized - pharmacology |
4 |
|
antigens, cd56 - metabolism |
4 |
|
antigens, cd95 - genetics - metabolism |
4 |
|
antigens, neoplasm - metabolism |
4 |
|
antineoplastic agents - economics - therapeutic use |
4 |
|
antineoplastic agents, phytogenic - adverse effects |
4 |
|
antineoplastic combined chemotherapy protocols - economics - therapeutic use |
4 |
|
antinuclear antibody |
4 |
|
antitubercular agents - therapeutic use |
4 |
|
apoptosis - physiology |
4 |
|
arsenic trioxide |
4 |
|
arsenicals - therapeutic use |
4 |
|
arthritis, rheumatoid - chemically induced |
4 |
|
asian continental ancestry group - genetics |
4 |
|
aspartate aminotransferases - blood |
4 |
|
b-lymphocytes - immunology |
4 |
|
bilirubin - blood |
4 |
|
biological markers - metabolism |
4 |
|
bk virus - genetics - isolation & purification |
4 |
|
bk virus - isolation & purification |
4 |
|
bone marrow - immunology |
4 |
|
bone marrow - pathology - physiopathology |
4 |
|
bone marrow transplantation - adverse effects - methods - pathology |
4 |
|
bone marrow transplantation - statistics & numerical data |
4 |
|
breast cancer |
4 |
|
breast neoplasms - drug therapy - enzymology - genetics - pathology |
4 |
|
busulfan - adverse effects - therapeutic use |
4 |
|
camptothecin - adverse effects - analogs & derivatives |
4 |
|
carrier state - epidemiology - immunology - microbiology |
4 |
|
cd4-cd8 ratio |
4 |
|
cell proliferation |
4 |
|
chemicals and cas registry numbers |
4 |
|
chemotherapy |
4 |
|
chemotherapy, adjuvant |
4 |
|
china - ethnology |
4 |
|
chinese patients |
4 |
|
chloramphenicol succinate |
4 |
|
chromatography, high pressure liquid |
4 |
|
chromosome deletion |
4 |
|
chromosomes, human, pair 12 |
4 |
|
chromosomes, human, pair 14 |
4 |
|
chronic lymphocytic leukemia |
4 |
|
clarithromycin |
4 |
|
clarithromycin - administration & dosage - pharmacology - toxicity |
4 |
|
clinical observations |
4 |
|
clinical trials as topic |
4 |
|
clonorchiasis |
4 |
|
colorectal neoplasms - drug therapy |
4 |
|
colorectal neoplasms - drug therapy - enzymology - pathology |
4 |
|
complication |
4 |
|
computer systems |
4 |
|
cord blood transplantation |
4 |
|
cost-benefit analysis |
4 |
|
cryptococcosis - blood - chemically induced |
4 |
|
cyclin-dependent kinase inhibitor p16 - metabolism |
4 |
|
cyclophosphamide - therapeutic use |
4 |
|
cystitis - diagnosis - etiology - virology |
4 |
|
cystitis - etiology - pathology - urine - virology |
4 |
|
cytomegalovirus - genetics - isolation & purification |
4 |
|
cytomegalovirus infections - blood - diagnosis - epidemiology |
4 |
|
daunorubicin - administration & dosage |
4 |
|
deep vein thrombosis |
4 |
|
diastole |
4 |
|
dna - analysis |
4 |
|
dna, neoplasm |
4 |
|
dna, neoplasm - genetics |
4 |
|
dna, viral - analysis - blood - urine |
4 |
|
dna, viral - genetics - isolation & purification |
4 |
|
drug delivery systems |
4 |
|
drug resistance, neoplasm |
4 |
|
echocardiography, doppler, pulsed |
4 |
|
embryo, mammalian - physiology |
4 |
|
embryo, nonmammalian |
4 |
|
embryo, nonmammalian - cytology - metabolism |
4 |
|
embryo, nonmammalian - metabolism |
4 |
|
epigenesis, genetic - drug effects - physiology |
4 |
|
epstein-barr virus |
4 |
|
erbb-2 |
4 |
|
event-free survival |
4 |
|
flt3/internal tandem duplication |
4 |
|
fungemia - blood - chemically induced |
4 |
|
gastric lymphoma |
4 |
|
gastrointestinal hemorrhage - etiology |
4 |
|
gene expression regulation, developmental |
4 |
|
gene expression regulation, developmental - drug effects |
4 |
|
gene expression regulation, neoplastic - drug effects |
4 |
|
gene rearrangement, beta-chain t-cell antigen receptor |
4 |
|
gene silencing - drug effects - physiology |
4 |
|
genes, immunoglobulin |
4 |
|
genes, tumor suppressor |
4 |
|
genetic predisposition to disease |
4 |
|
glucocorticoids - therapeutic use |
4 |
|
graft versus host disease |
4 |
|
graft vs host disease - complications - immunology |
4 |
|
graft vs host disease - epidemiology - etiology - microbiology |
4 |
|
graft-versus-host disease |
4 |
|
green fluorescent proteins - metabolism |
4 |
|
gut toxicity |
4 |
|
gvhd |
4 |
|
haemoglobin h disease |
4 |
|
haploinsufficiency |
4 |
|
hb bart's disease |
4 |
|
helicobacter infections - immunology |
4 |
|
helicobacter pylori |
4 |
|
hematopoiesis - drug effects - genetics - physiology |
4 |
|
hematopoiesis, extramedullary - physiology |
4 |
|
hematopoietic stem cells |
4 |
|
hematopoietic stem cells - cytology - metabolism |
4 |
|
hematopoietic stem cells - cytology - physiology |
4 |
|
hematuria - diagnosis - etiology - virology |
4 |
|
hemoglobin f |
4 |
|
hemoglobinopathies - blood - complications - therapy |
4 |
|
hemoglobins - analysis |
4 |
|
hemoglobins, abnormal |
4 |
|
hemorrhage - etiology - pathology - surgery - virology |
4 |
|
hepatitis - drug therapy - etiology - pathology |
4 |
|
hepatitis b - complications - drug therapy - virology |
4 |
|
hepatitis b - drug therapy - etiology - pathology |
4 |
|
hepatitis b - epidemiology |
4 |
|
hepatitis b - mortality - therapy - virology |
4 |
|
hepatitis b surface antigens - analysis |
4 |
|
hepatitis b surface antigens - metabolism |
4 |
|
hepatitis b virus - genetics - immunology |
4 |
|
hepatitis b virus - growth & development |
4 |
|
hepatitis b virus - physiology |
4 |
|
hepatitis b, chronic - drug therapy - immunology |
4 |
|
hepatitis b, chronic - etiology - immunology - transmission |
4 |
|
herpes zoster |
4 |
|
herpes zoster - epidemiology - etiology - pathology |
4 |
|
herpesvirus 4, human - genetics |
4 |
|
histocompatibility |
4 |
|
histocompatibility testing - methods |
4 |
|
hla mismatched |
4 |
|
homozygote |
4 |
|
icm |
4 |
|
immune thrombocytopenia |
4 |
|
immunosuppressive agents - adverse effects - therapeutic use |
4 |
|
infection |
4 |
|
inhibitor of apoptosis proteins - genetics |
4 |
|
iron - metabolism |
4 |
|
iron chelating agents - adverse effects - therapeutic use |
4 |
|
iron overload - drug therapy - etiology - physiopathology - ultrasonography |
4 |
|
janus kinase 2 - genetics |
4 |
|
kidney - cytology - metabolism |
4 |
|
kidney transplantation |
4 |
|
kidneys |
4 |
|
leukemia stem cells |
4 |
|
leukemia, promyelocytic, acute - drug therapy |
4 |
|
leukemia, promyelocytic, acute - drug therapy - mortality |
4 |
|
leukemia, promyelocytic, acute - drug therapy - mortality - therapy |
4 |
|
leukemia, t-cell - genetics - immunology - mortality - pathology |
4 |
|
life tables |
4 |
|
liver - metabolism |
4 |
|
liver diseases - drug therapy - etiology - pathology |
4 |
|
liver diseases - etiology - pathology |
4 |
|
liver failure, acute - epidemiology - etiology |
4 |
|
lung - microbiology - pathology - radiography |
4 |
|
lymphoma - diagnosis - pathology - therapy |
4 |
|
lymphoma, b-cell - genetics |
4 |
|
lymphoma, b-cell - metabolism - pathology - radionuclide imaging |
4 |
|
lymphoma, follicular - drug therapy - immunology |
4 |
|
lymphoma, non-hodgkin - diagnosis - drug therapy - radiotherapy |
4 |
|
lymphoma, non-hodgkin - drug therapy - immunology |
4 |
|
lymphoma, t-cell - genetics - immunology - mortality - pathology |
4 |
|
lymphoma, t-cell - immunology - pathology |
4 |
|
lymphoma, t-cell - metabolism - pathology - radionuclide imaging |
4 |
|
lymphoma, t-cell, peripheral - diagnosis - drug therapy - radiotherapy |
4 |
|
magnetic resonance imaging - methods |
4 |
|
methylation |
4 |
|
microenvironment |
4 |
|
mir203 |
4 |
|
molecular probes - genetics |
4 |
|
mouth mucosa |
4 |
|
mtor |
4 |
|
multiple myeloma |
4 |
|
multiple myeloma - etiology - genetics |
4 |
|
multiple myeloma - pathology |
4 |
|
multiple myeloma - therapy |
4 |
|
myelodysplastic syndromes - genetics |
4 |
|
myelodysplastic syndromes - genetics - metabolism |
4 |
|
myeloproliferative disease |
4 |
|
nasal lymphoma |
4 |
|
natural killer cell lymphoma |
4 |
|
natural killer cell lymphoma/leukaemia |
4 |
|
neoplasm proteins - analysis |
4 |
|
neoplasm staging |
4 |
|
neoplasm, residual - diagnosis |
4 |
|
neovascularization, physiologic - genetics |
4 |
|
nod/scid mice |
4 |
|
non-hodgkin lymphoma |
4 |
|
nose neoplasms - diagnosis - drug therapy - radiotherapy |
4 |
|
nose neoplasms - diagnosis - pathology - therapy |
4 |
|
nose neoplasms - genetics - pathology |
4 |
|
oncogene proteins, fusion - analysis |
4 |
|
oral chelator |
4 |
|
oral mucositis |
4 |
|
oxides - therapeutic use |
4 |
|
pad |
4 |
|
papillomavirus infections - diagnosis - etiology - virology |
4 |
|
papillomavirus infections - etiology - pathology |
4 |
|
pcna |
4 |
|
pet/ct |
4 |
|
pi3 kinase |
4 |
|
plasmacytoma - complications - pathology |
4 |
|
polyomavirus infections - blood - urine - virology |
4 |
|
positron-emission tomography |
4 |
|
postoperative complications - blood - urine - virology |
4 |
|
precursor cell lymphoblastic leukemia-lymphoma - drug therapy - therapy |
4 |
|
prednisolone - therapeutic use |
4 |
|
primary cell culture |
4 |
|
proliferating cell nuclear antigen - genetics - metabolism |
4 |
|
purpura, thrombocytopenic - ethnology - immunology - physiopathology - therapy |
4 |
|
purpura, thrombocytopenic, idiopathic - drug therapy - etiology |
4 |
|
purpura, thrombocytopenic, idiopathic - drug therapy - genetics - immunology |
4 |
|
pyridones - adverse effects - therapeutic use |
4 |
|
quantitative pcr |
4 |
|
receptor, erbb-2 - antagonists & inhibitors - biosynthesis - genetics - metabolism |
4 |
|
renal transplantation |
4 |
|
respiratory function tests |
4 |
|
risk assessment |
4 |
|
rna, messenger - metabolism |
4 |
|
salvage therapy |
4 |
|
sheep - embryology |
4 |
|
splenectomy |
4 |
|
stem cell transplantation - adverse effects - methods |
4 |
|
stem cells - chemistry - physiology |
4 |
|
steroids - therapeutic use |
4 |
|
stomach neoplasms - complications - pathology |
4 |
|
stomatitis - drug therapy - prevention & control |
4 |
|
survival |
4 |
|
suv max |
4 |
|
t-cell receptor delta |
4 |
|
t-lymphocytes - pathology |
4 |
|
therapeutic irrigation - methods |
4 |
|
therapeutic trials |
4 |
|
tomography, emission-computed |
4 |
|
topoisomerase i inhibitors |
4 |
|
transplantation chimera |
4 |
|
transplantation conditioning - adverse effects - methods |
4 |
|
transplantation immunology |
4 |
|
transplantation, homologous - adverse effects - immunology - methods |
4 |
|
trastuzumab |
4 |
|
tretinoin - pharmacology |
4 |
|
tretinoin - therapeutic use |
4 |
|
trisomy |
4 |
|
tuberculosis, pulmonary - drug therapy - etiology - immunology - physiopathology - |
4 |
|
tumor markers, biological - genetics |
4 |
|
tumor virus infections - blood - urine - virology |
4 |
|
tumor virus infections - etiology - pathology |
4 |
|
tumour suppressor |
4 |
|
urinary bladder - metabolism - pathology |
4 |
|
varicella-zoster virus |
4 |
|
vascular endothelial growth factor a - genetics |
4 |
|
venous thrombosis |
4 |
|
ventricular function, left |
4 |
|
vidarabine - adverse effects - analogs & derivatives |
4 |
|
viremia - virology |
4 |
|
virology - methods - standards |
4 |
|
whole-body irradiation |
4 |
|
zebrafish - embryology - genetics - physiology |
4 |
|
21) |
3 |
|
5-azacytidine |
3 |
|
6-mercaptopurine - administration & dosage |
3 |
|
actuarial analysis |
3 |
|
adenovirus |
3 |
|
adrenal cortex hormones - therapeutic use |
3 |
|
adrenal gland neoplasms - complications |
3 |
|
adrenal insufficiency - drug therapy - etiology |
3 |
|
adrenocortical insufficiency. |
3 |
|
adult acute leukemias |
3 |
|
adult wilm's tumour |
3 |
|
age-adjusted international index |
3 |
|
aldehyde dehydrogenase |
3 |
|
aldehyde dehydrogenase - antagonists & inhibitors - physiology |
3 |
|
allogeneic |
3 |
|
allogeneic bmt |
3 |
|
allogeneic bone-marrow transplantation (bmt) |
3 |
|
alpha-thalassemia |
3 |
|
alpha-thalassemia - blood - classification - genetics - physiopathology |
3 |
|
alpha-thalassemia - complications - genetics |
3 |
|
anemia, aplastic - therapy |
3 |
|
anemia, macrocytic - etiology |
3 |
|
anemia, megaloblastic - epidemiology - etiology - pathology |
3 |
|
anemia, pernicious - complications |
3 |
|
angiolymphoid hyperplasia with eosinophilia - etiology - genetics - pathology |
3 |
|
angiolymphoid hyperplasia with eosinophilia - genetics |
3 |
|
angiolymphoid hyperplasia with eosinophilia - genetics - pathology |
3 |
|
angiosarcoma |
3 |
|
anti-bacterial agents |
3 |
|
antibiotics, antineoplastic - therapeutic use |
3 |
|
antigens, cd - metabolism |
3 |
|
antigens, cd20 - analysis |
3 |
|
antigens, cd34 - analysis |
3 |
|
antigens, cd4 - analysis |
3 |
|
antigens, cd79 |
3 |
|
antilymphocyte serum - therapeutic use |
3 |
|
antineoplastic agents - administration & dosage - adverse effects |
3 |
|
antineoplastic agents, alkylating - adverse effects - therapeutic use |
3 |
|
antineoplastic agents, phytogenic - administration & dosage |
3 |
|
antineoplastic combined chemotherapy protocols - administration & dosage |
3 |
|
antineoplastic combined chemotherapy protocols - administration & dosage - adverse effects |
3 |
|
antineoplastic combined chemotherapy protocols - pharmacology - therapeutic use |
3 |
|
antirheumatic agents - administration & dosage - adverse effects |
3 |
|
apoptosis regulatory proteins |
3 |
|
apoptosis regulatory proteins - genetics |
3 |
|
arsenicals - administration & dosage |
3 |
|
arsenicals - administration & dosage - pharmacology |
3 |
|
aryl hydrocarbon hydroxylases |
3 |
|
asparaginase - administration & dosage |
3 |
|
asparaginase - administration & dosage - adverse effects |
3 |
|
atg |
3 |
|
atp-binding cassette transporters - analysis |
3 |
|
autoimmune diseases |
3 |
|
autoimmune diseases - complications - drug therapy - metabolism |
3 |
|
autoimmune thyroid disease |
3 |
|
autologous bone marrow transplantation |
3 |
|
autologous stem cell transplantation |
3 |
|
autopsy |
3 |
|
azathioprine |
3 |
|
b |
3 |
|
bacteraemia |
3 |
|
bcl-2 |
3 |
|
bcl-6 |
3 |
|
bcl-6 gene |
3 |
|
bcl10 |
3 |
|
beta 2-microglobulin - analysis |
3 |
|
beta catenin - chemistry |
3 |
|
beta-thalassemia - epidemiology |
3 |
|
bleomycin - administration & dosage - adverse effects |
3 |
|
blood donors |
3 |
|
blood transfusion |
3 |
|
blood transfusion, autologous |
3 |
|
bmt recipients |
3 |
|
bone marrow - drug effects - metabolism |
3 |
|
bone marrow - drug effects - physiology |
3 |
|
bone marrow cells - pathology |
3 |
|
bone marrow cells - physiology |
3 |
|
bone marrow cells - virology |
3 |
|
bone marrow transplantation - immunology - methods - mortality |
3 |
|
boronic acids - pharmacology |
3 |
|
brain neoplasms - epidemiology - metabolism - pathology |
3 |
|
breast neoplasms - pathology |
3 |
|
burkitt lymphoma - drug therapy - etiology - metabolism - virology |
3 |
|
carboplatin - administration & dosage |
3 |
|
carmustine - administration & dosage |
3 |
|
carrier proteins - metabolism |
3 |
|
caspase 3 |
3 |
|
caspases |
3 |
|
caspases - drug effects - metabolism |
3 |
|
catheters, indwelling - adverse effects |
3 |
|
cd4/cd56 |
3 |
|
cdkn2a |
3 |
|
cdkn2b |
3 |
|
cell aging |
3 |
|
cell count |
3 |
|
cell cycle |
3 |
|
cell cycle proteins |
3 |
|
cell differentiation - drug effects |
3 |
|
cell division |
3 |
|
cell line |
3 |
|
cell line, tumor - drug effects - metabolism |
3 |
|
cell lineage |
3 |
|
cell nucleus - metabolism |
3 |
|
cell proliferation - drug effects |
3 |
|
cell proliferation/drug effects* |
3 |
|
cell transformation, neoplastic |
3 |
|
cell transformation, viral - drug effects |
3 |
|
cells, cultured |
3 |
|
central venous catheter |
3 |
|
ceop |
3 |
|
chi-square distribution |
3 |
|
chickenpox vaccine - administration & dosage |
3 |
|
chinese people |
3 |
|
chloramphenicol |
3 |
|
chloramphenicol - analogs & derivatives - analysis - pharmacology - toxicity |
3 |
|
chloramphenicol - analogs and derivatives - metabolism |
3 |
|
cholecystectomy |
3 |
|
cholelithiasis - blood - etiology - genetics |
3 |
|
chondrocytes - metabolism |
3 |
|
chromosome aberrations |
3 |
|
chromosomes, human, pair 11 |
3 |
|
chromosomes, human, pair 11 - genetics - ultrastructure |
3 |
|
chromosomes, human, pair 14 - genetics - ultrastructure |
3 |
|
chromosomes, human, pair 15 |
3 |
|
chromosomes, human, pair 20 |
3 |
|
chromosomes, human, pair 21 |
3 |
|
chromosomes, human, pair 3 |
3 |
|
chromosomes, human, pair 4 |
3 |
|
chromosomes, human, pair 8 |
3 |
|
chromosomes, human, pair 9 |
3 |
|
chronic lymphoproliferative disorders |
3 |
|
chronic myeloid leukaemia (cml) |
3 |
|
chronic myeloid leukemia |
3 |
|
clinical presentation |
3 |
|
cml |
3 |
|
cns disease |
3 |
|
collagen type x - genetics - immunology - physiology |
3 |
|
colonic neoplasms - drug therapy - pathology |
3 |
|
complete remission |
3 |
|
computed tomography |
3 |
|
cpg island |
3 |
|
cpg islands |
3 |
|
croup |
3 |
|
cyclin d1 - metabolism |
3 |
|
cyclin-dependent kinase inhibitor p15 |
3 |
|
cyclin-dependent kinase inhibitor p15 - metabolism |
3 |
|
cyclin-dependent kinase inhibitor proteins - genetics |
3 |
|
cyclophosphamide |
3 |
|
cyclophosphamide - administration & dosage - adverse effects |
3 |
|
cyclosporine |
3 |
|
cyclosporine - therapeutic use |
3 |
|
cytarabine - administration and dosage - adverse effects |
3 |
|
cytochrome p-450 enzyme system - genetics |
3 |
|
cytogenetics |
3 |
|
cytoplasmic granules - ultrastructure |
3 |
|
cytotoxic t-lymphocytes precursor frequency |
3 |
|
dacarbazine - administration & dosage |
3 |
|
de novo aml |
3 |
|
dendritic cells - metabolism - pathology |
3 |
|
dexamethasone - administration & dosage |
3 |
|
diamond-blackfan syndrome |
3 |
|
diffuse large b-cell lymphoma |
3 |
|
disease models, animal |
3 |
|
dna chimerism |
3 |
|
dna fragmentation |
3 |
|
dna methylation - drug effects |
3 |
|
dna probes |
3 |
|
dna, circular - analysis |
3 |
|
dna, neoplasm - analysis - genetics |
3 |
|
dna, neoplasm - chemistry - genetics |
3 |
|
dna-binding proteins |
3 |
|
dna-binding proteins - physiology |
3 |
|
doxorubicin - administration & dosage - adverse effects |
3 |
|
drug evaluation |
3 |
|
drug resistance |
3 |
|
drug synergism |
3 |
|
drug therapy |
3 |
|
drug therapy, combination - administration & dosage |
3 |
|
dyskeratosis congenita |
3 |
|
ebv |
3 |
|
embryo, nonmammalian - physiology |
3 |
|
embryonic development |
3 |
|
endothelium, vascular - injuries |
3 |
|
engraftment |
3 |
|
enzyme activation |
3 |
|
enzyme inhibitors - pharmacology |
3 |
|
epirubicin - administration & dosage |
3 |
|
epstein-barr virus infections - immunology |
3 |
|
erythroid precursor cells - metabolism |
3 |
|
erythropoiesis - drug effects - physiology |
3 |
|
extracellular matrix - metabolism |
3 |
|
extramedullary plasmacytoma |
3 |
|
eye neoplasms - diagnosis - pathology - therapy |
3 |
|
eyelid diseases - etiology |
3 |
|
failure-free survival |
3 |
|
fibroblast growth factor 1 - administration & dosage |
3 |
|
flow cytometry - methods |
3 |
|
flt-3 aberrations |
3 |
|
fusion proteins, bcr-abl |
3 |
|
fusion proteins, bcr-abl - genetics |
3 |
|
gallbladder neoplasms - diagnosis - pathology - surgery |
3 |
|
gallstones |
3 |
|
gallstones - etiology - genetics |
3 |
|
ganciclovir |
3 |
|
gene deletion |
3 |
|
gene expression profiling - methods |
3 |
|
gene expression regulation - drug effects - genetics |
3 |
|
gene expression regulation - genetics |
3 |
|
gene expression regulation, neoplastic - genetics |
3 |
|
gene rearrangement, gamma-chain t-cell antigen receptor |
3 |
|
gene targeting - methods |
3 |
|
genes, p16 |
3 |
|
genes, p16 - genetics |
3 |
|
genes, t-cell receptor - genetics |
3 |
|
gilbert disease - blood - etiology - genetics |
3 |
|
gilbert syndrome |
3 |
|
glycoproteins - administration & dosage |
3 |
|
glycoproteins - metabolism |
3 |
|
glycosaminoglycans - metabolism |
3 |
|
graft vs host disease - immunology |
3 |
|
graft vs tumor effect |
3 |
|
graft-versus-host disease (gvhd) |
3 |
|
granular lymphocytes |
3 |
|
granulocyte colony-stimulating factor |
3 |
|
granulocyte precursor cells - physiology |
3 |
|
granulocytic sarcoma |
3 |
|
granuloma, lethal midline - diagnosis |
3 |
|
granuloma, lethal midline - diagnosis - pathology - therapy |
3 |
|
green fluorescent proteins - genetics |
3 |
|
haplotypes |
3 |
|
hbh disease |
3 |
|
heart neoplasms - diagnosis - pathology |
3 |
|
helper t-cell precursor frequency |
3 |
|
hemangiosarcoma - drug therapy - pathology - surgery |
3 |
|
hematologic malignancy |
3 |
|
hematologic neoplasms - mortality - therapy |
3 |
|
hematologic-neoplasms-drug-therapy |
3 |
|
hematological cancers |
3 |
|
hematology |
3 |
|
hematopoiesis - drug effects |
3 |
|
hematopoietic stem cell transplantation - utilization |
3 |
|
hematopoietic stem cells - cytology |
3 |
|
hematopoietic stem cells - drug effects - physiology |
3 |
|
hematopoietic system |
3 |
|
hemochromatosis - complications - genetics |
3 |
|
hemoglobin h - analysis - genetics |
3 |
|
hemoglobin h disease |
3 |
|
hemoglobins - biosynthesis - drug effects |
3 |
|
hemoglobinuria - blood - classification - genetics |
3 |
|
hepatitis b |
3 |
|
hepatitis b - drug therapy - virology |
3 |
|
hepatitis b - etiology - mortality |
3 |
|
hepatitis b - surgery |
3 |
|
hepatitis b antibodies - analysis |
3 |
|
hepatitis b surface antigens - analysis - immunology |
3 |
|
hepatitis b virus - genetics |
3 |
|
hepatitis b, chronic - complications - drug therapy - metabolism |
3 |
|
hepatitis-b-prevention-and-control |
3 |
|
hepatitis-b-virus-physiology |
3 |
|
herpes zoster - prevention & control |
3 |
|
herpesvirus 4, human |
3 |
|
herpesvirus 4, human - metabolism |
3 |
|
hfe gene |
3 |
|
histocompatibility antigens class i - analysis |
3 |
|
histocompatibility antigens class i - genetics |
3 |
|
hla |
3 |
|
hla class 1,immune escape |
3 |
|
hla haplotype |
3 |
|
hla-a2 antigen |
3 |
|
hla-b antigens |
3 |
|
hla-dr serological subtypes |
3 |
|
hla-identical siblings |
3 |
|
hodgkin disease - drug therapy - mortality - pathology |
3 |
|
hodgkin's disease |
3 |
|
hong kong - ethnology |
3 |
|
human bone marrow |
3 |
|
human bone marrow and liver |
3 |
|
hydrocortisone - therapeutic use |
3 |
|
hydroxyurea |
3 |
|
hydroxyurea - therapeutic use |
3 |
|
hyperthyroidism |
3 |
|
hypothyroidism |
3 |
|
idarubicin |
3 |
|
idarubicin - administration & dosage - pharmacology |
3 |
|
ifn-γ-producing cell frequency |
3 |
|
il2 |
3 |
|
immuno-reconstitution |
3 |
|
immunophenotype |
3 |
|
immunosuppressive agents - adverse effects |
3 |
|
intensive chemotherapy |
3 |
|
intercellular signaling peptides and proteins - administration & dosage |
3 |
|
intercellular signaling peptides and proteins - genetics - metabolism |
3 |
|
intercellular signaling peptides and proteins - metabolism |
3 |
|
interleukin-10 |
3 |
|
interleukin-10 - analysis |
3 |
|
interleukin-2 - pharmacology - physiology |
3 |
|
interleukin-6 |
3 |
|
interphase - genetics |
3 |
|
intestinal neoplasms - immunology - pathology |
3 |
|
intestinal polyps - pathology |
3 |
|
intracellular signaling peptides and proteins |
3 |
|
iron overload - blood - etiology - genetics |
3 |
|
janus kinase 1 |
3 |
|
janus kinase 2 - antagonists and inhibitors - genetics - metabolism |
3 |
|
janus kinase 2 - genetics - physiology |
3 |
|
jaundice |
3 |
|
jaundice - etiology - genetics |
3 |
|
kaplan-meier estimate |
3 |
|
karyotypic changes |
3 |
|
kidney - drug effects - physiology |
3 |
|
kidney neoplasms - drug therapy - pathology - surgery |
3 |
|
killer cells, natural - cytology - metabolism |
3 |
|
killer cells, natural - drug effects - pathology |
3 |
|
killer cells, natural - radionuclide imaging |
3 |
|
kimura's disease |
3 |
|
lacrimal apparatus diseases - diagnosis - pathology - therapy |
3 |
|
lacrimal gland |
3 |
|
lamivudine - administration & dosage |
3 |
|
lamivudine-therapeutic-use |
3 |
|
large granular lymphocytic leukemia |
3 |
|
leucovorin - administration & dosage - adverse effects |
3 |
|
leukaemias |
3 |
|
leukemia, lymphoid - ethnology - pathology - therapy |
3 |
|
leukemia, megakaryoblastic, acute - genetics |
3 |
|
leukemia, monocytic, acute - genetics |
3 |
|
leukemia, myelogenous, chronic, bcr-abl positive - genetics - therapy |
3 |
|
leukemia, myelogenous, chronic, bcr-abl positive - immunology - therapy |
3 |
|
leukemia, myeloid - chemically induced - genetics - radionuclide imaging |
3 |
|
leukemia, myeloid - complications - therapy |
3 |
|
leukemia, myeloid - drug therapy - mortality |
3 |
|
leukemia, myeloid - epidemiology - pathology |
3 |
|
leukemia, myeloid - etiology - genetics |
3 |
|
leukemia, myeloid - genetics - physiopathology - therapy |
3 |
|
leukemia, myeloid, acute - blood - pathology |
3 |
|
leukemia, myeloid, acute - chemically induced |
3 |
|
leukemia, myeloid, acute - diagnosis - therapy |
3 |
|
leukemia, myeloid, acute - drug therapy - mortality |
3 |
|
leukemia, myeloid, acute - genetics - mortality |
3 |
|
leukemia, myelomonocytic, acute - pathology |
3 |
|
leukemia, promyelocytic, acute - blood - drug therapy - genetics - pathology |
3 |
|
leukemia, promyelocytic, acute - diagnosis - genetics |
3 |
|
leukemia, promyelocytic, acute - genetics - immunology - mortality |
3 |
|
leukemia, t-cell - drug therapy - pathology |
3 |
|
limiting dilution assay |
3 |
|
literature review |
3 |
|
liver - drug effects - physiology |
3 |
|
liver transplantation - adverse effects |
3 |
|
logistic models |
3 |
|
lung neoplasms - diagnosis |
3 |
|
lymphocyte transfusion |
3 |
|
lymphoma - complications - drug therapy - metabolism - virology |
3 |
|
lymphoma - diagnosis - pathology |
3 |
|
lymphoma - drug therapy - pathology |
3 |
|
lymphoma - drug therapy - radiotherapy - therapy |
3 |
|
lymphoma - epidemiology - metabolism - pathology |
3 |
|
lymphoma relapses post-hsct |
3 |
|
lymphoma, b-cell - complications - drug therapy |
3 |
|
lymphoma, b-cell - drug therapy - pathology |
3 |
|
lymphoma, b-cell - genetics - metabolism - pathology |
3 |
|
lymphoma, b-cell - genetics - pathology |
3 |
|
lymphoma, b-cell, marginal zone - diagnosis - pathology - surgery |
3 |
|
lymphoma, b-cell, marginal zone - drug therapy - pathology |
3 |
|
lymphoma, b-cell, marginal zone - genetics |
3 |
|
lymphoma, extranodal nk-t-cell - metabolism |
3 |
|
lymphoma, large b-cell, diffuse - drug therapy |
3 |
|
lymphoma, large b-cell, diffuse - genetics |
3 |
|
lymphoma, large b-cell, diffuse - mortality |
3 |
|
lymphoma, mantle-cell - drug therapy - metabolism - pathology |
3 |
|
lymphoma, non-hodgkin - complications |
3 |
|
lymphoma, non-hodgkin - diagnosis |
3 |
|
lymphoma, non-hodgkin - ethnology - genetics - mortality - pathology - therapy |
3 |
|
lymphoma, t-cell - complications - drug therapy |
3 |
|
lymphoma, t-cell - diagnosis |
3 |
|
lymphoma, t-cell - drug therapy - pathology |
3 |
|
lymphoma, t-cell - immunology |
3 |
|
lymphoma, t-cell - metabolism - pathology - virology |
3 |
|
lymphoma, t-cell - pathology - radionuclide imaging |
3 |
|
lymphoma, t-cell - therapy |
3 |
|
lymphoma, t-cell, peripheral - diagnosis |
3 |
|
lymphoproliferative diseases |
3 |
|
lymphoproliferative disorders - epidemiology - pathology |
3 |
|
lymphoproliferative disorders - therapy |
3 |
|
mantle cell lymphoma |
3 |
|
masquerade |
3 |
|
mechlorethamine - administration & dosage |
3 |
|
mediastinal neoplasms - drug therapy - pathology |
3 |
|
megaloblastic anaemia |
3 |
|
melphalan - administration & dosage |
3 |
|
melphalan - adverse effects - therapeutic use |
3 |
|
melphalan - therapeutic use |
3 |
|
meningeal neoplasms - chemically induced - genetics - radionuclide imaging |
3 |
|
metabolism |
3 |
|
methotrexate |
3 |
|
methotrexate - administration & dosage - adverse effects |
3 |
|
methylation-specific polymerase chain reaction |
3 |
|
methylprednisolone - therapeutic use |
3 |
|
mice |
3 |
|
mice, scid |
3 |
|
micrornas - antagonists and inhibitors - genetics |
3 |
|
microtubule-associated proteins - physiology |
3 |
|
minimal residual disease (mro) |
3 |
|
mir129 |
3 |
|
mitochondria - drug effects - physiology |
3 |
|
mitosis |
3 |
|
mitoxantrone |
3 |
|
mitoxantrone - administration and dosage - adverse effects |
3 |
|
morpholines - administration & dosage |
3 |
|
multiple myeloma - diagnosis - drug therapy - genetics |
3 |
|
multiple myeloma - diagnosis - mortality - therapy |
3 |
|
multiple myeloma - diagnosis - pathology - physiopathology - therapy |
3 |
|
multiple myeloma - genetics |
3 |
|
multiple myeloma - genetics - metabolism - pathology |
3 |
|
multiple myeloma - genetics - pathology - therapy |
3 |
|
multiple myeloma - physiopathology |
3 |
|
multiple myeloma/pathology* |
3 |
|
multivariate analysis |
3 |
|
muscle neoplasms - diagnosis |
3 |
|
muscle, skeletal |
3 |
|
mutagenesis - drug effects |
3 |
|
myeloablative agents |
3 |
|
myeloablative agonists - adverse effects |
3 |
|
myelodysplasia |
3 |
|
myelodysplastic syndromes - chemically induced |
3 |
|
myelofibrosis |
3 |
|
myeloid |
3 |
|
nasal cavity |
3 |
|
nasal nk/t lymphoma |
3 |
|
nasal nk/t-cell lymphoma |
3 |
|
nasopharyngeal neoplasms - pathology |
3 |
|
nasopharyngeal neoplasms - surgery |
3 |
|
natural killer-like t-cell lymphoma |
3 |
|
naturalkiller cell lymphoma |
3 |
|
neoplasm proteins - blood |
3 |
|
neoplasm proteins - genetics - physiology |
3 |
|
neoplasm, residual - genetics |
3 |
|
neoplasms - complications - therapy |
3 |
|
neoplasms - therapy |
3 |
|
neoplasms, second primary - chemically induced |
3 |
|
neoplasms, second primary - chemically induced - genetics - radionuclide imaging |
3 |
|
neoplastic stem cells - metabolism - pathology |
3 |
|
neovascularization, physiologic |
3 |
|
neutropenia - epidemiology |
3 |
|
neutrophils |
3 |
|
nf-kappa b - genetics - metabolism |
3 |
|
nf-κ |
3 |
|
nose neoplasms - diagnosis |
3 |
|
nose neoplasms - drug therapy - radiotherapy - therapy |
3 |
|
nose neoplasms - immunology |
3 |
|
nose neoplasms - therapy |
3 |
|
nucleus |
3 |
|
octamer transcription factor-2 - analysis |
3 |
|
oligoclonal reconstitution |
3 |
|
oligonucleotide array sequence analysis |
3 |
|
oligonucleotides, antisense - administration & dosage |
3 |
|
oncogene proteins, fusion - blood |
3 |
|
oncology |
3 |
|
organ specificity |
3 |
|
outcome |
3 |
|
outcome assessment (health care) |
3 |
|
oxidation-reduction |
3 |
|
oxidative stress |
3 |
|
oxides - administration & dosage |
3 |
|
oxides - administration & dosage - pharmacology |
3 |
|
p15 |
3 |
|
p16 |
3 |
|
pancytopenia - etiology |
3 |
|
parainfluenza virus |
3 |
|
paramyxoviridae infections - chemically induced - complications |
3 |
|
paraproteinemias - genetics |
3 |
|
pathological diagnosis |
3 |
|
pericardium - pathology |
3 |
|
peripheral blood |
3 |
|
ph-negative leukaemia |
3 |
|
phenotype |
3 |
|
philadelphia chromosome |
3 |
|
phospholipase c gamma - drug effects - genetics - physiology |
3 |
|
pilot projects |
3 |
|
plasmacytoid dendritic cell tumor |
3 |
|
plasmacytoma - diagnosis - pathology - therapy |
3 |
|
platelet-derived growth factor - administration & dosage |
3 |
|
point mutation |
3 |
|
point mutation - genetics |
3 |
|
polycythemia vera - enzymology - genetics - pathology |
3 |
|
polycythemia vera - ethnology - physiopathology |
3 |
|
polymorphism, single nucleotide - genetics |
3 |
|
poor engraftment |
3 |
|
positron emission tomography |
3 |
|
postoperative complications |
3 |
|
postoperative period |
3 |
|
precursor cell lymphoblastic leukemia-lymphoma - drug therapy |
3 |
|
precursor cell lymphoblastic leukemia-lymphoma - drug therapy - mortality |
3 |
|
precursor cell lymphoblastic leukemia-lymphoma - genetics - mortality |
3 |
|
precursor cell lymphoblastic leukemia-lymphoma - pathology - therapy |
3 |
|
precursor cell lymphoblastic leukemia-lymphoma - therapy |
3 |
|
prednisolone - administration & dosage |
3 |
|
prednisone - administration & dosage - adverse effects |
3 |
|
primary brain lymphoma |
3 |
|
primary cardiac lymphoma |
3 |
|
primary gastrointestinal lymphoma |
3 |
|
primary mediastinal lymphoma |
3 |
|
primary myelofibrosis - epidemiology |
3 |
|
primary myelofibrosis - genetics |
3 |
|
procarbazine - administration & dosage |
3 |
|
profiling |
3 |
|
prostatic neoplasms - drug therapy - metabolism - pathology |
3 |
|
protease inhibitors - therapeutic use |
3 |
|
protein processing, post-translational |
3 |
|
protein synthesis inhibitors - analysis |
3 |
|
protein tyrosine phosphatase, non-receptor type 6 |
3 |
|
protein tyrosine phosphatases - metabolism |
3 |
|
protein-tyrosine kinases - antagonists and inhibitors - genetics - metabolism |
3 |
|
protein-tyrosine kinases - metabolism |
3 |
|
proteoglycans - metabolism |
3 |
|
proto-oncogene proteins |
3 |
|
proto-oncogene proteins - metabolism |
3 |
|
proto-oncogene proteins c-akt - metabolism |
3 |
|
proto-oncogene proteins c-bcl-2 |
3 |
|
pure red cell aplasia |
3 |
|
pyrazines - pharmacology |
3 |
|
pyrazines - therapeutic use |
3 |
|
quality of life |
3 |
|
questionnaires |
3 |
|
radiography, thoracic |
3 |
|
rat liver and kidney mitochondria |
3 |
|
rats |
3 |
|
receptors, antigen, b-cell - analysis |
3 |
|
receptors, transferrin - deficiency - genetics |
3 |
|
receptors, tumor necrosis factor - administration & dosage - genetics - metabolism |
3 |
|
recombinant proteins - pharmacology |
3 |
|
red-cell aplasia, pure - physiopathology - therapy |
3 |
|
regeneration |
3 |
|
relapsed apl |
3 |
|
repressor proteins - metabolism |
3 |
|
respiratory tract infections - chemically induced - complications |
3 |
|
restriction mapping |
3 |
|
retreatment |
3 |
|
reverse transcriptase inhibitors - administration & dosage |
3 |
|
risk |
3 |
|
rna, messenger - blood - genetics |
3 |
|
safety |
3 |
|
sars virus - isolation & purification |
3 |
|
secondary aml |
3 |
|
severe acute respiratory syndrome |
3 |
|
severe acute respiratory syndrome - diagnosis - drug therapy |
3 |
|
severe aplastic anemia |
3 |
|
sex characteristics |
3 |
|
siblings |
3 |
|
splenomegaly |
3 |
|
splenomegaly - complications |
3 |
|
stat1 transcription factor |
3 |
|
stat5 transcription factor - metabolism |
3 |
|
steroid 16-alpha-hydroxylase |
3 |
|
steroid hydroxylases - genetics |
3 |
|
stomach neoplasms - diagnosis - secondary |
3 |
|
stromal cells - cytology |
3 |
|
succinate dehydrogenase |
3 |
|
succinate dehydrogenase - antagonists & inhibitors - pharmacology |
3 |
|
suppressor of cytokine signaling proteins |
3 |
|
t(8 |
3 |
|
t-cell |
3 |
|
t-lymphocytes, cytotoxic - immunology |
3 |
|
t-lymphocytes, helper-inducer - immunology |
3 |
|
t/nk cell lymphoma |
3 |
|
tandem repeat sequences |
3 |
|
tap 1 |
3 |
|
tcr and igh genes rearrangement |
3 |
|
teniposide - administration & dosage |
3 |
|
tfr2 gene |
3 |
|
thalassemia |
3 |
|
therapy-related lymphoma |
3 |
|
thiazolidinediones/pharmacology* |
3 |
|
thrombocythemia, essential - complications - drug therapy - mortality |
3 |
|
thrombocythemia, essential - complications - genetics - mortality - physiopathology |
3 |
|
thrombocytopenia - complications - therapy |
3 |
|
thrombocytopenia - epidemiology |
3 |
|
thrombocytosis - blood - genetics - physiopathology |
3 |
|
thrombocytosis - complications - drug therapy |
3 |
|
thrombosis |
3 |
|
thrombosis - complications |
3 |
|
thrombosis - epidemiology |
3 |
|
thrombosis - etiology - genetics |
3 |
|
thrombosis-free survival |
3 |
|
thymectomy |
3 |
|
thyroiditis, autoimmune - etiology |
3 |
|
thyroiditis, autoimmune - immunology |
3 |
|
trans-activators - physiology |
3 |
|
transcription factors |
3 |
|
transcription factors - metabolism |
3 |
|
transcriptional activation |
3 |
|
transformation |
3 |
|
transplant related mortality |
3 |
|
transplantation chimera - genetics |
3 |
|
transplantation, autologous - utilization |
3 |
|
transplantation, heterologous |
3 |
|
treatment |
3 |
|
tretinoin - administration & dosage |
3 |
|
tretinoin/pharmacology* |
3 |
|
tumor markers, biological - blood |
3 |
|
tumor suppressor |
3 |
|
tumor suppressor proteins |
3 |
|
tumour suppressor gene |
3 |
|
up-regulation - drug effects - genetics |
3 |
|
uterine neoplasms - metabolism - secondary - virology |
3 |
|
uterus |
3 |
|
vad |
3 |
|
vascular endothelial growth factor a - administration & dosage |
3 |
|
vascular neoplasms - diagnosis |
3 |
|
venous thrombosis - etiology |
3 |
|
vinblastine - administration & dosage |
3 |
|
vincristine - administration & dosage - adverse effects |
3 |
|
virus-activation-drug-effects |
3 |
|
vitamin b 12 deficiency - complications |
3 |
|
vitamin b12 deficiency |
3 |
|
vocal cords - pathology |
3 |
|
voice disorders - diagnosis - etiology - virology |
3 |
|
warfarin - adverse effects |
3 |
|
wilms tumor - drug therapy - pathology - surgery |
3 |
|
wnt proteins - physiology |
3 |
|
zebrafish - embryology |
3 |
|
zebrafish - embryology - genetics |
3 |
|
zebrafish - embryology - genetics - metabolism |
3 |
|
zebrafish proteins - antagonists and inhibitors - genetics - metabolism |
3 |
|
zebrafish proteins - genetics - metabolism |
3 |
|
zebrafish proteins - physiology |
3 |
|
β-catenin |
3 |
|
β2-microglobulin |
3 |
|
*hemoglobin e/genetics |
2 |
|
*hemoglobins, abnormal/genetics |
2 |
|
5' untranslated regions |
2 |
|
acute gvhd |
2 |
|
acute leukaemia |
2 |
|
acute leukemia |
2 |
|
acute myeloblastic leukemia |
2 |
|
agranulocytosis |
2 |
|
agranulocytosis - complications |
2 |
|
alemtuzumab |
2 |
|
alk1 |
2 |
|
allogeneic hematopoietic cell transplantation |
2 |
|
alpha-thalassemia - complications |
2 |
|
amino acid sequence |
2 |
|
anemia, aplastic - genetics |
2 |
|
anemia, hemolytic, autoimmune - etiology |
2 |
|
ankylosing spondylitis |
2 |
|
anti-hbs |
2 |
|
anti-viral therapy |
2 |
|
antibodies, monoclonal - immunology |
2 |
|
antigens, cd30 |
2 |
|
antigens, differentiation - analysis |
2 |
|
antineoplastic agents - adverse effects - therapeutic use |
2 |
|
antineoplastic combined chemotherapy protocols - administration & dosage - therapeutic use |
2 |
|
antineoplastic combined chemotherapy protocols - adverse effects |
2 |
|
antithyroid agents |
2 |
|
apaf-1 |
2 |
|
apoptosis/drug effects* |
2 |
|
apoptotic protease-activating factor 1 |
2 |
|
arginine - chemistry |
2 |
|
arginine - genetics |
2 |
|
arthritis, rheumatoid - complications - drug therapy |
2 |
|
asparaginase - metabolism |
2 |
|
atra |
2 |
|
autologous hematopoietic stem cell transplantation |
2 |
|
azathioprine - adverse effects |
2 |
|
b-cell lymphoma |
2 |
|
b-lymphocytes |
2 |
|
b-lymphocytes - physiology |
2 |
|
b-lymphocytes - virology |
2 |
|
back pain - etiology |
2 |
|
bacterial infections - complications - drug therapy - microbiology |
2 |
|
beta-thalassemia - surgery |
2 |
|
biological markers - blood |
2 |
|
blast crisis |
2 |
|
bmp |
2 |
|
bone marrow - analysis - immunology |
2 |
|
bone marrow cells - cytology |
2 |
|
bone marrow neoplasms - diagnosis - pathology |
2 |
|
bone morphogenetic protein 4 |
2 |
|
bone morphogenetic proteins - physiology |
2 |
|
bone neoplasms - diagnosis |
2 |
|
bone neoplasms - diagnosis - secondary |
2 |
|
brain neoplasms - complications |
2 |
|
brain/radiography |
2 |
|
breast neoplasms, male - diagnosis - secondary |
2 |
|
british columbia - epidemiology |
2 |
|
bronchiolitis obliterans |
2 |
|
bronchiolitis obliterans - etiology |
2 |
|
bronchiolitis obliterans - pathology - physiopathology |
2 |
|
burkitt lymphoma |
2 |
|
burkitt lymphoma - genetics |
2 |
|
burkitt's lymphoma |
2 |
|
calcium-calmodulin-dependent protein kinases - genetics |
2 |
|
carcinoma - etiology - genetics |
2 |
|
carcinoma, signet ring cell - diagnosis - pathology |
2 |
|
carotid arteries/radiography |
2 |
|
carotid body tumor - complications - pathology |
2 |
|
carrier proteins - genetics |
2 |
|
caspase-3 |
2 |
|
cause of death |
2 |
|
cell apoptosis |
2 |
|
cell cycle proteins - genetics |
2 |
|
cell differentiation |
2 |
|
central nervous system - pathology |
2 |
|
central nervous system neoplasms - diagnosis - secondary |
2 |
|
cerebral angiography |
2 |
|
cerebral infarction |
2 |
|
cerebral infarction/etiology |
2 |
|
cerebrovascular disorders |
2 |
|
chordin |
2 |
|
chromosomal abnormality |
2 |
|
chromosome mapping |
2 |
|
chromosomes, human, pair 17 |
2 |
|
chromosomes, human, pair 18 |
2 |
|
chromosomes, human, pair 3 - genetics |
2 |
|
chromosomes, human, pair 7 |
2 |
|
cilia - physiology - ultrastructure |
2 |
|
ciliary function |
2 |
|
ciliary motility disorders - complications - etiology |
2 |
|
ciliary motility disorders - drug therapy - pathology - physiopathology |
2 |
|
cll |
2 |
|
clonal |
2 |
|
clonality of tumours |
2 |
|
coculture techniques |
2 |
|
codon - genetics |
2 |
|
colectomy |
2 |
|
colonic neoplasms - diagnosis - pathology - surgery |
2 |
|
colonoscopy |
2 |
|
compartment syndrome |
2 |
|
compartment syndromes |
2 |
|
cross-cultural comparison |
2 |
|
cross-cultural translation |
2 |
|
cyclin-dependent kinases - metabolism |
2 |
|
cytokine gene expression |
2 |
|
cytokines |
2 |
|
cytokines - genetics - metabolism |
2 |
|
cytokines - metabolism |
2 |
|
dap kinase |
2 |
|
denileukin diftitox |
2 |
|
differentiation |
2 |
|
dna - genetics |
2 |
|
dna - viral |
2 |
|
dna ligases - deficiency |
2 |
|
dna replication |
2 |
|
dna, complementary - analysis |
2 |
|
dna, neoplasm - analysis |
2 |
|
dna, viral - chemistry |
2 |
|
donor follow-up |
2 |
|
donor lymphocyte infusion |
2 |
|
dosage compensation, genetic |
2 |
|
dose-response relationship, drug |
2 |
|
dot blot hybridization |
2 |
|
double labelling |
2 |
|
doxorubicin - therapeutic use |
2 |
|
drug-induced liver injury - etiology |
2 |
|
dyskeratosis congenita - therapy |
2 |
|
embryo, nonmammalian - embryology - metabolism |
2 |
|
endemic diseases |
2 |
|
environmental health |
2 |
|
epstein barr virus |
2 |
|
epstein-barr virus infections - complications - immunology |
2 |
|
epstein-barr virus infections - complications - virology |
2 |
|
epstein-barr virus nuclear antigens - genetics - metabolism |
2 |
|
europe - epidemiology |
2 |
|
extra-medullary disease |
2 |
|
extramedullary disease |
2 |
|
extramedullary relapse |
2 |
|
extranodal |
2 |
|
extranodal lymphoma |
2 |
|
fact-bmt |
2 |
|
factor v - genetics |
2 |
|
factor v - genetics - metabolism |
2 |
|
factor v deficiency - complications - ethnology - genetics |
2 |
|
far east |
2 |
|
fever - etiology |
2 |
|
fluorescent antibody technique |
2 |
|
fms-like tyrosine kinase 3 |
2 |
|
forecasting |
2 |
|
gastrointestinal neoplasms |
2 |
|
gastrointestinal neoplasms - diagnosis |
2 |
|
gastrointestinal neoplasms - mortality - pathology - therapy |
2 |
|
gene amplification |
2 |
|
gene duplication |
2 |
|
gene expression regulation, viral |
2 |
|
gene rearrangement - genetics |
2 |
|
gene rearrangement, b-lymphocyte - genetics |
2 |
|
gene rearrangement, b-lymphocyte, heavy chain - genetics |
2 |
|
genes |
2 |
|
genes, immunoglobulin - genetics |
2 |
|
genome, viral |
2 |
|
glucose 6-phosphate dehydrogenase (g6pd) deficiency |
2 |
|
glycoproteins - physiology |
2 |
|
graft survival - drug effects |
2 |
|
graft vs host disease - blood - diagnosis - etiology |
2 |
|
graft vs host disease - blood - etiology |
2 |
|
graft vs host disease - ethnology |
2 |
|
graft vs host disease - mortality |
2 |
|
graft-versus- leukemia effect |
2 |
|
granulocyte-macrophage colony-stimulating factor - therapeutic use |
2 |
|
granuloma, lethal midline - pathology - therapy |
2 |
|
greenhouse effect |
2 |
|
gynecomastia |
2 |
|
gynecomastia - diagnosis |
2 |
|
gynecomastia - etiology - pathology |
2 |
|
haemoglobin h |
2 |
|
hairy cell leukemia |
2 |
|
hd |
2 |
|
health |
2 |
|
heart neoplasms - drug therapy - secondary |
2 |
|
hematologic diseases - ethnology - therapy |
2 |
|
hematopoiesis - genetics |
2 |
|
hematopoiesis, extramedullary |
2 |
|
hepatitis b - chemically induced - microbiology - mortality |
2 |
|
hepatitis b - chronic |
2 |
|
hepatitis b - complications |
2 |
|
hepatitis b - immunology - transmission |
2 |
|
hepatitis b e antigens - isolation & purification |
2 |
|
hepatitis b surface antigens - isolation & purification |
2 |
|
hepatitis b virus - classification - genetics - immunology |
2 |
|
hepatitis b virus - isolation & purification |
2 |
|
hepatitis b, chronic - complications - drug therapy |
2 |
|
hepatitis b, chronic - complications - therapy |
2 |
|
hepatitis b, chronic - drug therapy - mortality - prevention & control |
2 |
|
hepatitis b, chronic - drug therapy - prevention & control |
2 |
|
hepatomegaly - etiology |
2 |
|
herpesviridae infections - complications |
2 |
|
herpesviridae infections - microbiology - pathology |
2 |
|
herpesvirus 4, human - genetics - isolation & purification - metabolism - pathogenicity |
2 |
|
heterosexuality |
2 |
|
histone deacetylase inhibitors |
2 |
|
hla b27 |
2 |
|
hla-b27 antigen |
2 |
|
hla-indentical siblings |
2 |
|
hodgkin disease - diagnosis - drug therapy - pathology |
2 |
|
hodgkin disease - pathology - prevention & control - radiotherapy |
2 |
|
hong kong chinese |
2 |
|
hsp90 heat-shock proteins - chemistry - genetics |
2 |
|
iaps |
2 |
|
immunity |
2 |
|
immunoglobulin gene |
2 |
|
immunoglobulin gene rearrangement |
2 |
|
immunoglobulin joining region - genetics |
2 |
|
immunoglobulin light chains - genetics |
2 |
|
immunoglobulin variable region - genetics |
2 |
|
immunoglobulins - genetics |
2 |
|
indium radioisotopes - diagnostic use |
2 |
|
intercellular signaling peptides and proteins - physiology |
2 |
|
interferons - genetics - metabolism |
2 |
|
interleukins - genetics - metabolism |
2 |
|
intermediate grade |
2 |
|
international cooperation |
2 |
|
intracellular signaling peptides and proteins - genetics |
2 |
|
intracerebral lymphoma |
2 |
|
intracranial embolism and thrombosis/*complications/radiography |
2 |
|
iron |
2 |
|
iron overload - blood - diagnosis - etiology |
2 |
|
ki-1 alcl |
2 |
|
klinefelter syndrome - complications |
2 |
|
language |
2 |
|
leadership |
2 |
|
leukemia - etiology |
2 |
|
leukemia - genetics |
2 |
|
leukemia - genetics - immunology |
2 |
|
leukemia - immunology |
2 |
|
leukemia, hairy cell - epidemiology - pathology |
2 |
|
leukemia, lymphocytic, chronic - genetics |
2 |
|
leukemia, lymphocytic, chronic, b-cell - blood - genetics - immunology - pathology |
2 |
|
leukemia, lymphocytic, chronic, b-cell - genetics - immunology |
2 |
|
leukemia, lymphocytic, chronic, b-cell - genetics - pathology - physiopathology |
2 |
|
leukemia, lymphoid - drug therapy - pathology |
2 |
|
leukemia, lymphoid - genetics - pathology |
2 |
|
leukemia, lymphoid - pathology - therapy |
2 |
|
leukemia, myelogenous, chronic, bcr-abl positive - complications |
2 |
|
leukemia, myelogenous, chronic, bcr-abl positive - genetics - immunology - pathology |
2 |
|
leukemia, myelogenous, chronic, bcr-abl positive - pathology - therapy |
2 |
|
leukemia, myeloid - chemically induced - complications - genetics |
2 |
|
leukemia, myeloid - genetics |
2 |
|
leukemia, myeloid - genetics - metabolism - therapy |
2 |
|
leukemia, myeloid, acute - complications - pathology - therapy |
2 |
|
leukemia, myeloid, acute - genetics - immunology |
2 |
|
leukemia, myeloid, acute - genetics - pathology |
2 |
|
leukemia, myeloid, acute - genetics - therapy |
2 |
|
leukemia, myeloid, acute - therapy |
2 |
|
leukemia, promyelocytic, acute - drug therapy - pathology |
2 |
|
leukemia-lymphoma, adult t-cell - diagnosis - pathology |
2 |
|
leukemia-lymphoma, adult t-cell - pathology - therapy |
2 |
|
leukemic infiltration |
2 |
|
liver |
2 |
|
liver - drug effects |
2 |
|
liver - microbiology |
2 |
|
liver failure - etiology |
2 |
|
liver involvement |
2 |
|
liver neoplasms |
2 |
|
liver neoplasms - diagnosis - drug therapy - pathology |
2 |
|
lung - drug effects - physiopathology |
2 |
|
lung diseases - complications |
2 |
|
lupus erythematosus, systemic - complications - drug therapy |
2 |
|
lymph nodes - chemistry - immunology - pathology |
2 |
|
lymph nodes - pathology |
2 |
|
lymphocyte count |
2 |
|
lymphocyte subsets - metabolism |
2 |
|
lymphocytosis |
2 |
|
lymphoid leukemic cells |
2 |
|
lymphoid tissue - immunology |
2 |
|
lymphoma - complications |
2 |
|
lymphoma - complications - drug therapy |
2 |
|
lymphoma - complications - immunology - therapy |
2 |
|
lymphoma - epidemiology - genetics - immunology |
2 |
|
lymphoma - genetics - pathology |
2 |
|
lymphoma - immunology - pathology |
2 |
|
lymphoma - pathology - therapy |
2 |
|
lymphoma, b-cell - diagnosis - pathology |
2 |
|
lymphoma, b-cell - genetics - immunology - microbiology |
2 |
|
lymphoma, b-cell, marginal zone - genetics - pathology |
2 |
|
lymphoma, b-cell, marginal zone - pathology - virology |
2 |
|
lymphoma, extranodal nk-t-cell - diagnosis - mortality - therapy |
2 |
|
lymphoma, follicular - diagnosis - pathology - surgery |
2 |
|
lymphoma, large b-cell, diffuse - complications - pathology - physiopathology |
2 |
|
lymphoma, large b-cell, diffuse - diagnosis - pathology |
2 |
|
lymphoma, large b-cell, diffuse - drug therapy - pathology |
2 |
|
lymphoma, large-cell, anaplastic - drug therapy - pathology - surgery |
2 |
|
lymphoma, mantle-cell - diagnosis |
2 |
|
lymphoma, non-hodgkin - blood - genetics - immunology - pathology |
2 |
|
lymphoma, non-hodgkin - drug therapy - physiopathology |
2 |
|
lymphoma, non-hodgkin - genetics - immunology |
2 |
|
lymphoma, non-hodgkin - mortality - pathology - therapy |
2 |
|
lymphoma, t-cell - diagnosis - immunology - pathology |
2 |
|
lymphoma, t-cell - genetics - immunology - microbiology |
2 |
|
lymphoma, t-cell - microbiology - pathology |
2 |
|
lymphoma, t-cell, peripheral - complications - genetics - virology |
2 |
|
lymphoma, t-cell, peripheral - genetics - metabolism - pathology |
2 |
|
lymphoma, t-cell, peripheral - immunology - virology |
2 |
|
lymphoproliferative disorders - genetics - immunology - pathology |
2 |
|
lymphoproliferative disorders - microbiology - pathology |
2 |
|
ma6 |
2 |
|
magnetic resonance |
2 |
|
male breast |
2 |
|
malignant lymphoma |
2 |
|
mass screening - methods |
2 |
|
mediastinal neoplasms - genetics |
2 |
|
meningeal neoplasms - secondary - therapy |
2 |
|
mesenchymal stem cells - cytology |
2 |
|
mesoderm - metabolism |
2 |
|
microarray |
2 |
|
microbial sensitivity tests |
2 |
|
microsatellite repeats |
2 |
|
microscopy, electron, transmission |
2 |
|
mif |
2 |
|
migration |
2 |
|
molecular remission |
2 |
|
monitoring, physiologic |
2 |
|
monoclonal antibodies |
2 |
|
monoclonal antibody |
2 |
|
morpholino |
2 |
|
mucosa‐associated lymphoid tissue |
2 |
|
mucous membrane - immunology |
2 |
|
multiple myeloma - genetics - metabolism |
2 |
|
muscle neoplasms - complications - pathology - physiopathology |
2 |
|
muscle, skeletal - pathology |
2 |
|
mutagens |
2 |
|
mutation, missense |
2 |
|
myelodysplastic syndromes |
2 |
|
myelodysplastic syndromes - genetics - immunology |
2 |
|
myelodysplastic syndromes - genetics - metabolism - therapy |
2 |
|
myocardium - pathology |
2 |
|
n-ras mutation |
2 |
|
nasal lymphomas |
2 |
|
nasal t/nk cell lymphoma |
2 |
|
nasopharyngeal neoplasms - diagnosis - immunology - pathology |
2 |
|
nasopharyngeal neoplasms - genetics - immunology - microbiology |
2 |
|
neoplasms, second primary - etiology - genetics |
2 |
|
neoplasms, unknown primary - complications - diagnosis |
2 |
|
neoplastic stem cells - chemistry |
2 |
|
neutropenia - chemically induced - complications |
2 |
|
nitric oxide |
2 |
|
nitric oxide - blood |
2 |
|
nk/t-cell lymphoma |
2 |
|
non‐hodgkin's lymphomas |
2 |
|
nose neoplasms - mortality - pathology - therapy |
2 |
|
nose neoplasms - pathology - therapy |
2 |
|
nuclear pore complex proteins - genetics - metabolism - physiology |
2 |
|
nucleic acid hybridization |
2 |
|
occult hbv |
2 |
|
oligodeoxyribonucleotides |
2 |
|
p14 |
2 |
|
p15 methylation |
2 |
|
pancreas |
2 |
|
pancreas - pathology |
2 |
|
pancreatic neoplasms - mortality - pathology - surgery |
2 |
|
paraganglioma - diagnosis - secondary |
2 |
|
paraproteinemias - genetics - metabolism |
2 |
|
peripheral t cell lymphoma |
2 |
|
peripheral t cell lymphomas |
2 |
|
peripheral t-cell lymphomas |
2 |
|
ph + leukemia relapse |
2 |
|
physician's role |
2 |
|
piperazines - pharmacology |
2 |
|
plasma dna |
2 |
|
plasmacytoma - diagnosis |
2 |
|
politics |
2 |
|
polymorphism, restriction fragment length |
2 |
|
polyploidy |
2 |
|
post-transplant lymphoproliferative disease |
2 |
|
ppar |
2 |
|
precursor b-cell lymphoblastic leukemia-lymphoma - genetics |
2 |
|
precursor cell lymphoblastic leukemia-lymphoma - blood - genetics - immunology - pathology |
2 |
|
precursor cell lymphoblastic leukemia-lymphoma - genetics - immunology |
2 |
|
preoperative care |
2 |
|
prevalence of occult hbv |
2 |
|
primary anaplastic lymphoma |
2 |
|
primary hepatic lymphoma |
2 |
|
primary liver |
2 |
|
primary skeletal muscle lymphoma |
2 |
|
proteins - genetics |
2 |
|
proto-oncogene proteins c-mdm2 - genetics |
2 |
|
psychometric evaluation |
2 |
|
pulmonary diffusing capacity - drug effects |
2 |
|
pyrimidines - pharmacology |
2 |
|
quality of life - psychology |
2 |
|
quality of life instrument |
2 |
|
radiopharmaceuticals - diagnostic use |
2 |
|
receptor protein-tyrosine kinases - genetics |
2 |
|
recipient origin |
2 |
|
recombinant fusion proteins - genetics |
2 |
|
recombinant proteins - therapeutic use |
2 |
|
red-cell aplasia, pure - blood - drug therapy |
2 |
|
regression analysis |
2 |
|
repressor proteins - genetics |
2 |
|
respiratory function tests - methods |
2 |
|
respiratory mucosa - pathology |
2 |
|
retinoblastoma protein - metabolism |
2 |
|
retroperitoneal fibrosis - diagnosis |
2 |
|
retroperitoneal neoplasms - diagnosis - pathology |
2 |
|
rna, small nuclear - analysis |
2 |
|
rna, viral - analysis |
2 |
|
rosiglitazone |
2 |
|
sclerosis |
2 |
|
screening |
2 |
|
secondary malignancies |
2 |
|
sexually transmitted diseases, viral - immunology - transmission - virology |
2 |
|
skin neoplasms - immunology - pathology |
2 |
|
spinal cord compression - etiology |
2 |
|
spinal puncture |
2 |
|
spleen - pathology |
2 |
|
spondylitis, ankylosing - genetics |
2 |
|
sti571 |
2 |
|
stomach neoplasms - pathology - virology |
2 |
|
stromal cells - metabolism |
2 |
|
stromal suppression |
2 |
|
substance withdrawal syndrome |
2 |
|
t cell receptor gene |
2 |
|
t-cell lymphomas/leukemia |
2 |
|
t-lymphocytes - immunology |
2 |
|
t-lymphocytes - metabolism |
2 |
|
t-lymphocytes - microbiology |
2 |
|
t-lymphocytes, helper-inducer - cytology |
2 |
|
tetrazolium salts - pharmacology |
2 |
|
thalassaemia |
2 |
|
thalassemia/*complications/genetics |
2 |
|
therapy-related acute myeloid leukaemia/myelodysplasia |
2 |
|
thiazolidinediones - pharmacology |
2 |
|
thrombocythemia, essential - complications - genetics - therapy |
2 |
|
tonsillar neoplasms - diagnosis - immunology - pathology |
2 |
|
trans-activators - genetics - metabolism |
2 |
|
translating |
2 |
|
translocation, genetic - genetics |
2 |
|
transplantation conditioning - adverse effects |
2 |
|
transplantation conditioning - methods |
2 |
|
transplantation, isogeneic - adverse effects |
2 |
|
tumor necrosis factor-alpha - genetics - metabolism |
2 |
|
tumor necrosis factor-alpha - metabolism |
2 |
|
tumor suppressor protein p14arf - genetics |
2 |
|
tumor suppressor proteins - genetics |
2 |
|
tumor virus infections - complications |
2 |
|
tumor virus infections - microbiology - pathology |
2 |
|
tumour environment |
2 |
|
type 1 |
2 |
|
type 2 |
2 |
|
t‐cell receptor gene rearrangements |
2 |
|
vincristine |
2 |
|
vincristine - pharmacology |
2 |
|
vincristine - therapeutic use |
2 |
|
viral matrix proteins - genetics - metabolism |
2 |
|
viral proteins - analysis |
2 |
|
virus activation - drug effects |
2 |
|
virus latency |
2 |
|
wif-1 |
2 |
|
wnt proteins - genetics |
2 |
|
world health |
2 |
|
zebrafish proteins |
2 |
|
zebrafish proteins - genetics - metabolism - physiology |
2 |
|
-308 ga polymorphism |
1 |
|
2-aminopurine - analogs & derivatives - therapeutic use |
1 |
|
aberrant methylation |
1 |
|
acquired factor viii inhibitor |
1 |
|
acquired immunodeficiency syndrome (aids) |
1 |
|
acute lymphoblastic leukaemia |
1 |
|
administration, cutaneous |
1 |
|
adoptive immunity transfer |
1 |
|
adrenal gland neoplasms - immunology |
1 |
|
advanced stage |
1 |
|
age |
1 |
|
age distribution |
1 |
|
aging - physiology |
1 |
|
airway obstruction - etiology |
1 |
|
alcohol drinking - adverse effects - prevention & control |
1 |
|
algorithms |
1 |
|
amphotericin b - therapeutic use |
1 |
|
amsacrine - administration & dosage - adverse effects - therapeutic use |
1 |
|
analysis of variance |
1 |
|
anemia, aplastic - blood - surgery |
1 |
|
anemia, aplastic - chemically induced - complications - pathology |
1 |
|
anemia, aplastic - pathology - therapy |
1 |
|
anemia, hemolytic |
1 |
|
anemia, sideroblastic - etiology - pathology |
1 |
|
angioplasty, balloon, coronary |
1 |
|
anti-bacterial agents - therapeutic use |
1 |
|
antibiotics, antineoplastic - adverse effects - therapeutic use |
1 |
|
antibodies, monoclonal - therapeutic use |
1 |
|
antifungal agents - therapeutic use |
1 |
|
antigens, cd2 |
1 |
|
antigens, cd3 |
1 |
|
antigens, cd7 |
1 |
|
antigens, differentiation, t-lymphocyte - analysis |
1 |
|
antigens, nuclear - genetics |
1 |
|
antineoplastic combined chemotherapy protocols |
1 |
|
aplastic anaemia |
1 |
|
aplastic anemia |
1 |
|
asia |
1 |
|
asian bone marrow transplantation |
1 |
|
asian continental ancestry group - ethnology |
1 |
|
autologous bone marrow transplanation |
1 |
|
bacteria - drug effects |
1 |
|
bcl-2/ighfusion |
1 |
|
bcl-6 polymorphism |
1 |
|
beta-thalassemia - complications |
1 |
|
beta-thalassemia - complications - ethnology - pathology |
1 |
|
blast crisis - drug therapy - mortality |
1 |
|
bleomycin - therapeutic use |
1 |
|
blood cell count |
1 |
|
bone marrow diseases - chemically induced |
1 |
|
bone marrow transplantation - statistics & numerical data - trends - utilization |
1 |
|
bone marrow transplantation costs |
1 |
|
bone neoplasms - mortality - pathology |
1 |
|
brain neoplasms - diagnosis - mortality - therapy |
1 |
|
brain neoplasms - pathology - secondary |
1 |
|
brain neoplasms - prevention & control - radiotherapy - secondary |
1 |
|
breast |
1 |
|
breast neoplasms - complications - pathology |
1 |
|
bronchiolitis obliterans - etiology - physiopathology |
1 |
|
burkitt lymphoma - complications - pathology |
1 |
|
cancer survivors |
1 |
|
cancer treatment |
1 |
|
candidiasis - diagnosis - drug therapy |
1 |
|
carcinoma, hepatocellular - etiology - virology |
1 |
|
carcinoma, papillary - genetics - immunology - therapy |
1 |
|
catheterization |
1 |
|
cbp |
1 |
|
cd4-positive t-lymphocytes - cytology - immunology - virology |
1 |
|
cd8-positive t-lymphocytes - cytology - immunology - virology |
1 |
|
ceftazidime - therapeutic use |
1 |
|
celiac disease - classification - mortality - pathology |
1 |
|
cell division - immunology |
1 |
|
central nervous system |
1 |
|
chemotherapy, adjuvant - adverse effects |
1 |
|
child - preschool |
1 |
|
cilastatin - administration & dosage - therapeutic use |
1 |
|
cilastatin - therapeutic use |
1 |
|
circadian rhythm - physiology |
1 |
|
cisplatin - administration & dosage |
1 |
|
clinical competence - standards |
1 |
|
clonal haematopoiesis |
1 |
|
combined modality therapy - adverse effects |
1 |
|
combined-modality therapy |
1 |
|
competency |
1 |
|
complications |
1 |
|
congenital coagulation factor deficiency |
1 |
|
conjunctival neoplasms - etiology - therapy |
1 |
|
conjunctival neoplasms - pathology - radiotherapy |
1 |
|
consensus |
1 |
|
coronary disease - blood - therapy |
1 |
|
cyclin-dependent kinase inhibitor p16 - genetics |
1 |
|
cytarabine - administration & dosage - adverse effects - therapeutic use |
1 |
|
daunorubicin - adverse effects - analogs & derivatives - therapeutic use |
1 |
|
dexamethasone - therapeutic use |
1 |
|
dipeptidases - antagonists & inhibitors |
1 |
|
diplopia - etiology |
1 |
|
disability evaluation |
1 |
|
dna polymerase iii - blood |
1 |
|
dna, viral - analysis - genetics |
1 |
|
dna, viral - genetics |
1 |
|
drug administration schedule |
1 |
|
drug combinations - therapeutic use |
1 |
|
drug therapy, combination - therapeutic use |
1 |
|
duodenal neoplasms - immunology - pathology |
1 |
|
education, medical, continuing - standards |
1 |
|
elderly |
1 |
|
elderly patients |
1 |
|
emigration and immigration |
1 |
|
empirical treatment |
1 |
|
endocrine system - physiopathology |
1 |
|
enteropathy-associated t-cell lymphoma - classification - mortality - pathology |
1 |
|
epidemiology |
1 |
|
epstein-barr virus infections - complications |
1 |
|
estradiol - administration & dosage - adverse effects - therapeutic use |
1 |
|
estrogen replacement therapy - adverse effects |
1 |
|
etretinate - adverse effects - therapeutic use |
1 |
|
european continental ancestry group |
1 |
|
evaluation studies as topic |
1 |
|
extranodal nk/t-cell lymphoma nasal type |
1 |
|
factor viii - antagonists & inhibitors |
1 |
|
famciclovir |
1 |
|
ferritins - metabolism |
1 |
|
fever - complications |
1 |
|
fever of unknown origin - complications - drug therapy |
1 |
|
flucytosine - therapeutic use |
1 |
|
focus groups |
1 |
|
follicular lymphoma |
1 |
|
follicular non‐hodgkin's lymphoma |
1 |
|
foundations |
1 |
|
gastrointestinal neoplasms - drug therapy - pathology - therapy |
1 |
|
gene frequency - genetics |
1 |
|
genes, bcl-2 - genetics |
1 |
|
genes, env |
1 |
|
genes, gag |
1 |
|
genes, pol |
1 |
|
genes, px |
1 |
|
genetic polymorphism |
1 |
|
genital neoplasms, female - diagnosis - immunology - therapy |
1 |
|
graft vs host disease - etiology - physiopathology |
1 |
|
gram-negative bacteria - drug effects |
1 |
|
great britain |
1 |
|
haematopoietic stem cell transplantation |
1 |
|
harringtonines - administration & dosage |
1 |
|
hbv |
1 |
|
hbv reactivation |
1 |
|
head and neck neoplasms - complications - therapy |
1 |
|
health care reform - standards |
1 |
|
health knowledge, attitudes, practice |
1 |
|
health status indicators |
1 |
|
health-related quality of life |
1 |
|
heart - physiology |
1 |
|
heart diseases - chemically induced |
1 |
|
heart diseases - pathology - therapy |
1 |
|
hematologic neoplasms - complications |
1 |
|
hematology - methods |
1 |
|
hematopoietic sct |
1 |
|
hematopoietic stem cell transplantation - ethnology - statistics and numerical data - trends |
1 |
|
hematopoietic stem cell transplantation - statistics & numerical data |
1 |
|
hematopoietic stem cell transplantation - statistics & numerical data - utilization |
1 |
|
hematuria - blood |
1 |
|
hemoglobinometry |
1 |
|
hemolytic anemia |
1 |
|
hemophilia a - complications - drug therapy |
1 |
|
hemorrhage - etiology |
1 |
|
hemosiderosis |
1 |
|
hemosiderosis - complications - ethnology - pathology |
1 |
|
hemosiderosis - etiology |
1 |
|
hemosiderosis - pathology - therapy |
1 |
|
hepatitis |
1 |
|
hepatitis b - blood - diagnosis - immunology - therapy |
1 |
|
hepatitis b - complications - epidemiology - microbiology |
1 |
|
hepatitis b - complications - prevention & control - therapy |
1 |
|
hepatitis b - diagnosis - etiology - prevention & control |
1 |
|
hepatitis b - drug therapy - immunology - prevention & control |
1 |
|
hepatitis b - etiology - physiopathology |
1 |
|
hepatitis b - immunology - pathology - therapy |
1 |
|
hepatitis b antibodies - immunology |
1 |
|
hepatitis b antigens - adverse effects |
1 |
|
hepatitis b core antigens - analysis - immunology |
1 |
|
hepatitis b core antigens - immunology |
1 |
|
hepatitis b e antigens - analysis |
1 |
|
hepatitis b e antigens - blood |
1 |
|
hepatitis b infection |
1 |
|
hepatitis b surface antigens - analysis - blood - immunology |
1 |
|
hepatitis b vaccines - administration & dosage |
1 |
|
hepatitis b virus - drug effects - growth & development |
1 |
|
hepatitis b virus - drug effects - physiology |
1 |
|
hepatitis b, chronic - drug therapy - virology |
1 |
|
hepatitis b, chronic - immunology - therapy |
1 |
|
hepatocellular carcinoma |
1 |
|
herpesvirus 4, human - genetics - isolation & purification |
1 |
|
high dose chemotherapy |
1 |
|
histocompatibility - genetics - immunology |
1 |
|
histology |
1 |
|
hla-a antigens - immunology |
1 |
|
hla-b antigens - immunology |
1 |
|
hla-dr antigens - immunology |
1 |
|
hodgkin disease - complications - mortality - therapy |
1 |
|
hodgkin disease - epidemiology |
1 |
|
hodgkin disease - genetics - pathology |
1 |
|
hodgkin disease - mortality - pathology - therapy |
1 |
|
hodgkin's lymphoma |
1 |
|
human immunodeficiency virus (hiv) |
1 |
|
human t-lymphotropic virus 1 - genetics |
1 |
|
human t-lymphotropic virus 1 - genetics - isolation & purification |
1 |
|
hydroxyurea - administration & dosage |
1 |
|
ifosfamide - administration & dosage |
1 |
|
ileal neoplasms - immunology - pathology |
1 |
|
imipenem - administration & dosage - therapeutic use |
1 |
|
imipenem - therapeutic use |
1 |
|
immunoproliferative disorders - diagnosis - pathology - therapy |
1 |
|
immunotherapy - methods |
1 |
|
immunotherapy, adoptive |
1 |
|
instrument |
1 |
|
interferon regulatory factors - genetics |
1 |
|
internationality |
1 |
|
interviews as topic |
1 |
|
intracellular signaling peptides and proteins/metabolism |
1 |
|
invasive fungal infection |
1 |
|
iron overload - etiology |
1 |
|
italy |
1 |
|
japan |
1 |
|
jejunal neoplasms - immunology - pathology |
1 |
|
l-asparaginase |
1 |
|
l-lactate dehydrogenase - analysis |
1 |
|
l-lactate dehydrogenase - blood |
1 |
|
laryngeal neoplasms - diagnosis - pathology - therapy |
1 |
|
leucovorin - therapeutic use |
1 |
|
leukemia - blood - surgery |
1 |
|
leukemia - drug therapy |
1 |
|
leukemia - drug therapy - mortality |
1 |
|
leukemia - pathology - therapy |
1 |
|
leukemia, lymphocytic, chronic, b-cell - epidemiology - genetics |
1 |
|
leukemia, lymphocytic, chronic, b-cell - genetics - metabolism - pathology |
1 |
|
leukemia, myelogenous, chronic, bcr-abl positive - complications - therapy |
1 |
|
leukemia, myeloid - complications - pathology |
1 |
|
leukemia, myeloid - diagnosis - etiology - pathology |
1 |
|
leukemia, myeloid - drug therapy |
1 |
|
leukemia, myeloid, acute - complications |
1 |
|
leukemia, myeloid, chronic-phase - drug therapy - mortality - pathology |
1 |
|
leukemia-lymphoma, adult t-cell - diagnosis |
1 |
|
leukemia-lymphoma, adult t-cell - virology |
1 |
|
liver - immunology - virology |
1 |
|
liver diseases - diagnosis - drug therapy |
1 |
|
liver diseases - etiology |
1 |
|
liver diseases - etiology - virology |
1 |
|
liver neoplasms - etiology - virology |
1 |
|
lomustine - therapeutic use |
1 |
|
long-term survivors |
1 |
|
low-grade lymphomas |
1 |
|
lymph nodes - chemistry - microbiology - pathology |
1 |
|
lymphatic diseases - pathology |
1 |
|
lymphoblastic lymphoma |
1 |
|
lymphocyte activation - immunology |
1 |
|
lymphoma - blood - surgery |
1 |
|
lymphoma - diagnosis - therapy |
1 |
|
lymphoma - drug therapy |
1 |
|
lymphoma - drug therapy - pathology - therapy |
1 |
|
lymphoma - epidemiology - pathology |
1 |
|
lymphoma, b-cell - complications - genetics - pathology |
1 |
|
lymphoma, b-cell - drug therapy - immunology - pathology |
1 |
|
lymphoma, b-cell - drug therapy - mortality - pathology |
1 |
|
lymphoma, b-cell - genetics - immunology - therapy |
1 |
|
lymphoma, b-cell - mortality - pathology |
1 |
|
lymphoma, b-cell - pathology - virology |
1 |
|
lymphoma, b-cell - therapy |
1 |
|
lymphoma, extranodal nk-t-cell - diagnosis - pathology - therapy |
1 |
|
lymphoma, follicular - epidemiology - genetics |
1 |
|
lymphoma, large b-cell, diffuse - etiology - pathology |
1 |
|
lymphoma, large b-cell, diffuse - genetics - immunology - therapy |
1 |
|
lymphoma, large b-cell, diffuse - immunology |
1 |
|
lymphoma, large b-cell, diffuse - pathology - virology |
1 |
|
lymphoma, mantle-cell - pathology - therapy |
1 |
|
lymphoma, non-hodgkin - classification |
1 |
|
lymphoma, non-hodgkin - complications - drug therapy |
1 |
|
lymphoma, non-hodgkin - diagnosis - immunology - therapy |
1 |
|
lymphoma, non-hodgkin - diagnosis - mortality - therapy |
1 |
|
lymphoma, non-hodgkin - drug therapy - epidemiology - pathology |
1 |
|
lymphoma, non-hodgkin - drug therapy - mortality - pathology |
1 |
|
lymphoma, non-hodgkin - drug therapy - pathology |
1 |
|
lymphoma, non-hodgkin - drug therapy - pathology - surgery |
1 |
|
lymphoma, non-hodgkin - drug therapy - radiotherapy - therapy |
1 |
|
lymphoma, non-hodgkin - ethnology |
1 |
|
lymphoma, non-hodgkin - mortality - pathology |
1 |
|
lymphoma, non-hodgkin - pathology |
1 |
|
lymphoma, non-hodgkin - pathology - therapy |
1 |
|
lymphoma, non-hodgkin - radiotherapy - therapy |
1 |
|
lymphoma, t-cell - classification - epidemiology - genetics - pathology |
1 |
|
lymphoma, t-cell - complications - genetics - microbiology |
1 |
|
lymphoma, t-cell - diagnosis - therapy |
1 |
|
lymphoma, t-cell - drug therapy - immunology - pathology |
1 |
|
lymphoma, t-cell - drug therapy - mortality - pathology |
1 |
|
lymphoma, t-cell - pathology - therapy |
1 |
|
lymphoma, t-cell, peripheral - classification - diagnosis - therapy |
1 |
|
lymphoma, t-cell, peripheral - classification - drug therapy - pathology |
1 |
|
lymphoma, t-cell, peripheral - classification - epidemiology - pathology |
1 |
|
lymphomas. |
1 |
|
management |
1 |
|
marrow donor registry |
1 |
|
measures |
1 |
|
mediastinal neoplasms - complications - radiography |
1 |
|
mediastinal neoplasms - therapy |
1 |
|
medicine - standards |
1 |
|
meningeal neoplasms - pathology - secondary |
1 |
|
mesna - administration & dosage |
1 |
|
methotrexate - therapeutic use |
1 |
|
microsatellite instability |
1 |
|
mitoxantrone - administration & dosage |
1 |
|
models, statistical |
1 |
|
molecular epidemiology |
1 |
|
monitoring, physiologic - methods |
1 |
|
mri |
1 |
|
mucositis - chemically induced - complications - diagnosis |
1 |
|
mucositis - diagnosis - etiology |
1 |
|
mucositis - etiology - physiopathology - psychology |
1 |
|
multiple myeloma - complications - pathology |
1 |
|
muscle neoplasms - pathology |
1 |
|
mycoses - prevention & control |
1 |
|
myelodysplastic syndrome |
1 |
|
myelodysplastic syndromes - complications |
1 |
|
myelodysplastic syndromes - complications - diagnosis - pathology |
1 |
|
myeloperoxidase deficiency |
1 |
|
myeloproliferative disorders - complications - genetics - pathology |
1 |
|
nasopharyngeal neoplasms - diagnosis - pathology - therapy |
1 |
|
nasopharyngeal neoplasms - radiotherapy - therapy |
1 |
|
nasopharyngeal neoplasms - secondary - virology |
1 |
|
nasopharyngeal neoplasms - therapy |
1 |
|
neoplasms - complications - drug therapy |
1 |
|
neoplasms - drug therapy |
1 |
|
neoplasms, second primary - etiology - therapy |
1 |
|
neoplasms, second primary - etiology - virology |
1 |
|
neprilysin |
1 |
|
neutropenia |
1 |
|
neutropenia - complications |
1 |
|
neutrophils - enzymology |
1 |
|
nk cell |
1 |
|
non-hodgkin’s lymphoma |
1 |
|
non-hodgkin’s lymphomas |
1 |
|
nose neoplasms - classification - epidemiology - genetics - pathology |
1 |
|
nose neoplasms - diagnosis - therapy |
1 |
|
ofloxacin - therapeutic use |
1 |
|
opportunistic infections - drug therapy |
1 |
|
orbit |
1 |
|
orbital neoplasms - diagnosis - pathology |
1 |
|
orbital neoplasms - pathology - therapy |
1 |
|
oropharyngeal mucositis |
1 |
|
oropharyngeal neoplasms - diagnosis - pathology - therapy |
1 |
|
oropharynx - drug effects - pathology |
1 |
|
ovary |
1 |
|
pain |
1 |
|
papua new guinea |
1 |
|
parotid gland |
1 |
|
parotid neoplasms - drug therapy - mortality - pathology |
1 |
|
partial thromboplastin time |
1 |
|
period of hospitalization |
1 |
|
peripheral blood stem cell |
1 |
|
peroxidase - deficiency |
1 |
|
pharyngeal diseases - etiology - physiopathology - psychology |
1 |
|
physicians |
1 |
|
pituitary gland - pathology |
1 |
|
poisson distribution |
1 |
|
polymorphic reticulosis |
1 |
|
polymorphism, single nucleotide |
1 |
|
pre-emptive treatment |
1 |
|
precursor cell lymphoblastic leukemia-lymphoma - etiology - pathology |
1 |
|
precursor cell lymphoblastic leukemia-lymphoma - immunology - pathology |
1 |
|
prednisone - therapeutic use |
1 |
|
pregnancy |
1 |
|
pregnancy complications, neoplastic - etiology - virology |
1 |
|
premedication |
1 |
|
primary gut lymphoma |
1 |
|
primary myelofibrosis - pathology - therapy |
1 |
|
probability |
1 |
|
procarbazine - administration & dosage - adverse effects |
1 |
|
procarbazine - therapeutic use |
1 |
|
prophylaxis |
1 |
|
protein losing enteropathy |
1 |
|
proviruses - genetics - isolation & purification |
1 |
|
psoriasis - drug therapy |
1 |
|
psychometric properties |
1 |
|
psychometrics |
1 |
|
psychometrics - methods |
1 |
|
purpura, thrombotic thrombocytopenic - chemically induced |
1 |
|
pyridoxine - therapeutic use |
1 |
|
quality of health care - standards |
1 |
|
radiotherapy |
1 |
|
radiotherapy, adjuvant |
1 |
|
radiotherapy, adjuvant - adverse effects |
1 |
|
randomized controlled trials as topic |
1 |
|
rasch analysis |
1 |
|
reactivation |
1 |
|
receptors, antigen, t-cell - analysis |
1 |
|
receptors, immunologic - analysis |
1 |
|
reform |
1 |
|
registries |
1 |
|
registry |
1 |
|
respiratory sounds - etiology |
1 |
|
rna, viral - isolation & purification |
1 |
|
role |
1 |
|
salvage chemotherapy |
1 |
|
sarcoma, myeloid - pathology - radiotherapy |
1 |
|
schools, medical - standards |
1 |
|
sequence alignment |
1 |
|
severe oral mucositis |
1 |
|
skeletal muscle |
1 |
|
skin |
1 |
|
skin - pathology |
1 |
|
skin neoplasms - diagnosis - etiology - pathology |
1 |
|
skin neoplasms - epidemiology - pathology - secondary |
1 |
|
social behavior |
1 |
|
specialist |
1 |
|
specialty boards - standards |
1 |
|
spinal cord neoplasms - diagnosis - mortality - therapy |
1 |
|
stage i and ii |
1 |
|
stage i–ii non‐hodgkin's lymphoma |
1 |
|
standard |
1 |
|
stem-cell transplantation |
1 |
|
stomach neoplasms - secondary |
1 |
|
stomatitis - epidemiology - etiology - physiopathology |
1 |
|
stomatitis - etiology - psychology |
1 |
|
superior vena cava syndrome - etiology |
1 |
|
survivors |
1 |
|
symptoms |
1 |
|
t cell |
1 |
|
t-cell lymphoma |
1 |
|
t-cell lymphomas |
1 |
|
t-immunophenotype |
1 |
|
t-lymphocytes |
1 |
|
testicular neoplasms - mortality - pathology |
1 |
|
thalassemia intermedia |
1 |
|
thioguanine - administration & dosage |
1 |
|
thioguanine - administration & dosage - adverse effects - therapeutic use |
1 |
|
thrombocytopenia - chemically induced |
1 |
|
thyroid lymphoma |
1 |
|
thyroid neoplasms - genetics - immunology - therapy |
1 |
|
thyroid neoplasms - mortality - pathology |
1 |
|
thyroiditis, autoimmune - genetics - immunology - therapy |
1 |
|
tnfα |
1 |
|
tonsillar neoplasms - radiotherapy - therapy |
1 |
|
transients and migrants - statistics & numerical data |
1 |
|
transplantation, homologous - physiology |
1 |
|
trimethoprim-sulfamethoxazole combination - therapeutic use |
1 |
|
tumor markers, biological - analysis |
1 |
|
tumor necrosis factor-alpha - genetics - physiology |
1 |
|
t‐immunophenotype |
1 |
|
ultrasonography |
1 |
|
unrelated bone marrow transplantation |
1 |
|
vaccination |
1 |
|
vagina |
1 |
|
vinblastine - therapeutic use |
1 |
|
virus activation - drug effects - physiology |
1 |
|
virus persistence |
1 |
|
vod |
1 |
|
waldeyer's ring |
1 |
|
world health organization |
1 |
